Podcasts about medical engineering

Limb Loss Awareness Month MIT: John McCollough   John is a student at MIT in Cambridge, Massachusetts working towards his Masters and PhD in Medical Engineering. I met him a year and half ago when he reached out to see if I was interested in coming to MIT for a Gait Study that he was assisting a student working toward his PhD. Of course I said Yes!   This is what it looks like when you agree to a gait study!     Now as time has flown by I have gone back to check on John's progress in the field of Biomechatronics, stayed connected with those in the lab and couldn't wait to have him on the podcast.     Once in the media Lab building you can see prototypes, unique sculptures, and their purpose and mission.   However, a quick disclaimer, some of the work being done in the MIT Media Lab, like other universities, is private and not up for discussion as they are still in the works of their projects in a very competitive field, but the topics we discuss today are amazing, eye-opening and incredibly groundbreaking and I can not wait for you all to hear what's on the cusp of becoming products and procedures available to the amputee community! John working on the project I took part in last year. Let's jump right into our conversation on the work being done with 3D printing, Oesteointegration, AMI procedure, and how students and university create, trademark, and market their designs and how long this process can take. Once again, I am blown away at the desires of these young men and women to create a better world for our amputee community. The future is looking so good and positive for us and I truly want these students to be seen for their hardwork and dedication to a community they are feeling led to assist. We are extremely blessed with what the future holds and I believe that the next 5, 10, 20 years we will see the struggles of amputees today become minimal if not obsolete, making our lives stronger, healthier, and physically complete. Join me this week as John and I discuss all things on the drawing board and please don't forget to Like, Share, and Subscribe so you don't miss any of these university students' conversations about the future of prosthetics.   John McCollough MIT Masters student Mechanical Engineering John, thank you for spending time we me on the podcast and sharing so eloquently the field of study you are in, breaking down the process so we could understand the stages of a study, and for sharing the work that could be shared. I look forward to having you on again as you complete your Masters and PhD. Thanks for joining us  and I hope you have a beautiful week ahead! And as always, until next time, Be Healthy, Be Happy, Be YOU!!!   Much love,  

The Reality of the Numbers and What We Can Do About It   The stats on amputees is staggering. In the US 1 in 200 people have undergone amputation! Over 2.1 million people live with an amputated limb. Worldwide, 1 million ampuatations happen annually, that's 1 amputation every 30 seconds!!!   1 EVERY 30 SECONDS! Amputee Coalition's diagram of statistics taken from Promedeast.com 2023   Even more alarming is the projection of the 2.1 million in the US doubling by the year 2050! (

In this episode, Hatem Rabeh will explain to us what are Clinical Data and also if there is a chance for you to avoid Clinical Investigations. There are also some confusion between Clinical Evaluation and Clinical Investigation. Let's clarify all this and give you the right strategies for your Medical Devices. So stay tuned.  Who is Hatem Rabeh?  Hatem Rabeh is a Medical Doctor with an MSc in Medical Engineering, specializing in clinical evaluation for medical devices.   With over 8 years of experience, he supports manufacturers in MDR compliance by preparing Clinical Evaluation Plans (CEP) and Clinical Evaluation Reports (CER) for Class I to Class III devices, including software, implants, and robotic systems.  His expertise covers literature reviews, clinical strategy, and regulatory compliance.   Hatem also shares his knowledge through online training, consulting, and LinkedIn content.  Who is Monir El Azzouzi?  Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland.  Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more.  Link Hatem Rabeh LinkedIn: https://www.linkedin.com/in/hatem-rabeh/  Social Media to follow Monir El Azzouzi Linkedin: https://linkedin.com/in/melazzouzi Twitter: https://twitter.com/elazzouzim Pinterest: https://www.pinterest.com/easymedicaldevice Instagram: https://www.instagram.com/easymedicaldevice

Meet the incredibly talented Victoria Kolmac, a university student with a passion for the intersection of biomedical engineering and computer science.Victoria shares her fascinating journey with us, outlining how she and her team built a pulse oximeter from scratch using Python and ESP32 microcontrollers, as well as her work on an advanced project aimed at non-invasively detecting thoracic pressure changes related to sleep apnea. We also delve into the world of quantum computing, exploring the basics of qubits and superposition and how Python is used for predictive modeling in this space. With personal stories of overcoming self-doubt and imposter syndrome, we emphasise the importance of perseverance in technical fields and highlight the real-world applications of Python in healthcare.Victoria's LinkedIn: https://www.linkedin.com/in/victoria-kolmac-a856b2249/Book Mention: "Nexus" - Yuval Noah Harari (https://pybitesbooks.com/books/n4rvEAAAQBAJ)Pybites Coaching: https://pybit.es/catalogue/the-pdm-program/___If you found this podcast helpful, please consider following us!For more Pybites:Developer Mindset Newsletter: https://pybit.es/newsletter

In this episode of the I'M NOT A BARISTA podcast, we sit down with Nikos Antzaras, a two-time Greek Barista Champion whose love for coffee transformed his life and career. Starting as a medical engineering student working as a barista to cover expenses, Nikos found his true calling in the world of coffee—a decision that led to both family tensions and remarkable personal growth."I really fell in love with coffee," Nikos recalls. Despite his parents' concerns—"What are you doing? Are you crazy? You studied... what coffee things are these?"—he pursued his passion relentlessly. Nikos shares valuable insights from his extensive experience in coffee competitions, emphasizing that "you never lose; you always win something." His journey took a profound turn during a trip to Colombia, where he helped save a coffee farmer's livelihood by challenging an incorrect defect evaluation. At his own establishment, Roast Warehouse in Athens, Nikos continues to inspire both customers and employees. "I always tell my employees, 'It doesn't matter where you work. If you love this job, you have to always give your 100 percent.'" With an open roastery concept, he invites everyone to witness the art and science behind every cup.Join us as we explore Nikos's inspiring story—a testament to passion, perseverance, and the impact one individual can have on an entire community. Whether you're a coffee professional or an enthusiast, this episode offers valuable lessons and motivation for your own journey in the world of coffee.www.notabarista.org

Jenea and Melyssa discuss Dr. Finley's journey into professorship as a computational researcher/mathematical biologist. --Dr. Stacey Finley is Professor of Biomedical Engineering and Quantitative & Computational Biology, at the University of Southern California and the inaugural holder of the Nichole A. and Thuan Q. Pham Professorship. Dr. Finley received her B.S. in Chemical Engineering from Florida A & M University and obtained her Ph.D. in Chemical Engineering from Northwestern University. She completed postdoctoral training at Johns Hopkins University in the Department of Biomedical Engineering. Dr. Finley joined the faculty at USC in 2013, and she leads the Computational Systems Biology Laboratory. Dr. Finley has a joint appointment in the Department of Chemical Engineering and Materials Science, and she is a member of the USC Norris Comprehensive Cancer Center. Dr. Finley is also a standing member of the MABS Study Section at NIH. Her research has been supported by grants from the NSF, NIH, and American Cancer Society.Selected honors. 2016 NSF Faculty Early CAREER Award; 2016 Young Innovator by the Cellular and Molecular Bioengineering journal; Leah Edelstein-Keshet Prize from the Society of Mathematical Biology; Junior Research Award from the USC Viterbi School of Engineering; the Hanna Reisler Mentorship Award; 2018 AACR NextGen Star; 2018 Orange County Engineering Council Outstanding Young Engineer; 2021 Elected Fellow of American Institute for Biological and Medical Engineering; 2022 Elected Fellow of the Biomedical Engineering SocietyLab website: https://csbl.usc.edu/ Lab Twitter: https://twitter.com/USCSysBio_LabFollow Dr. Finley's student, Diamond Mangrum, on Instagram (author of the paper referenced by Ijeoma in the episode): https://www.instagram.com/melanated.phd/?hl=en . She aims to demystify the Ph.D. process!------The CompBio Cafe Podcast is brewing up fresh perspectives in the CompBio world. Hosts Jenea Adams and Melyssa Minto, PhD are two trained computational biologists who serve the Black Women in Computational Biology Network (BWCB).Learn more about us at linktr.ee/bwcb.Subscribe to CompBio Cafe wherever you get your podcasts, and leave us a review once you've listened to a few episodes.

In this episode of Medsider Radio, we had a fun chat with Conor Cullinane, co-founder and CEO of Pirouette Medical. The company, founded by three rocket scientists, is developing a low-profile, disc-shaped injector designed to deliver medicines as easily as pushing a button.  Conor studied Aeronautical Engineering at Clarkson University and graduated with minors in Biomedical Engineering and Mathematics, followed by his PhD in Medical Engineering & Medical Physics at MIT and Harvard Medical School. He is also a mentor for Field X at Harvard Business School and a NASA Space Technology Research Fellow.In this interview, Conor shares learnings from launching a community fundraising round, insights on selective innovation, identifying different value propositions for diverse stakeholders, and building strong investor relationships.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Conor Cullinane.

Dr. Ha Hong, Ph.D. ( http://hahong.org/ ), is Chief Artificial Intelligence Officer at Medtronic Endoscopy ( https://www.medtronic.com/covidien/en-us/clinical-solutions/gastrointestinal-health.html ) where he oversees AI R&D and strategy, emphasizing building responsible AI solutions for patient care, and has a track record of inventing and delivering breakthrough technologies in the medical device field ( https://www.medtronic.com/covidien/en-us/products/gastrointestinal-artificial-intelligence/gi-genius-intelligent-endoscopy.html ). Before joining Medtronic, Dr. Hong was a founding team member and the Chief Architect at Caption Health, which GE HealthCare acquired, where he led the R&D, including the development of the first commercially available AI navigation system for cardiac ultrasound examination. Dr. Hong has a Ph.D. in Medical Engineering and Medical Physics from the Harvard-MIT Health Sciences and Technology Program and a BS in Physics from the Korea Advanced Institute of Science and Technology. Medtronic Edonscopy is part of Medtronic plc (https://www.medtronic.com/us-en/index.html), the world's largest medical device company, which operates in more than 150 countries and employs over 90,000 people. Important Episode Links Medtronic GI Genius™ Intelligent Endoscopy Module - https://www.medtronic.com/covidien/en-us/products/gastrointestinal-artificial-intelligence/gi-genius-intelligent-endoscopy.html Medtronic Artificial Intelligence (AI) Compass for responsible use of AI - https://www.medtronic.com/content/dam/medtronic-wide/public/brand-corporate-assets/resources/medtronic-ai-compass.pdf Dr. Ha Hong Linkedin Profile - https://www.linkedin.com/in/ha-hong/ Support the show

Jim Collins is one of the leading biomedical engineers in the world. He's been elected to all 3 National Academies (Engineering, Science, and Medicine) and is one of the founders of the field of synthetic biology. In this conversation, we reviewed the seminal discoveries that he and his colleagues are making at the Antibiotics-AI Project at MIT.Recorded 5 February 2024, transcript below with audio links and external links to recent publicationsEric Topol (00:05):Hello, it's Eric Topol with Ground Truths, and I have got an extraordinary guest with me today, Jim Collins, who's the Termeer Professor of Medical Engineering at MIT. He also holds appointments at the Wyss Institute and the Broad Institute. He is a biomedical engineer who's been making exceptional contributions and has been on a tear lately, especially in the work of discovery of very promising, exciting developments in antibiotics. So welcome, Jim.Jim Collins (00:42):Eric, thanks for having me on the podcast.Eric Topol (00:44):Well, this was a shock when I saw your paper in Nature in December about a new structure class of antibiotics, the one from 1962 to 2000. It took 38 years, and then there was another one that took 24 years yours, the structural antibiotics. Before I get to that though, I want to go back just a few years to the work you did published in Cell with halicin, and can you tell us about this? Because when I started to realize what you've been doing, what you've been chipping away here, this was a drug you found, halicin, as I can try to understand, it works against tuberculosis, c. difficile, enterobacter that are resistant, acinetobacter that are resistant. I mean, this is, and this is of course in mice models. Can you tell us how did you make that discovery before we get into I guess what's called the Audacious Project?Jim Collins (01:48):Yeah, sure. It's actually a fun story, so it is origins go broadly to institute wide event at MIT, so MIT in 2018 launched a major campus-wide effort focused on artificial intelligence. The institute, which had played a major role in the first wave of AI in the 1950s, 1960s, and a major wave in the second wave in the 1980s found itself kind of at the wheel in this third wave involving big data and deep learning and looked to correct that and to correct it the institute had a symposium and I had the opportunity to sit next to Regina Barzilay, one of our faculty here at MIT who specializes in AI and particularly AI applied to biomedicine and we really hit it off and realized we had interest in applying AI to drug discovery. My lab had focused on antibiotics to then close to 15 years, but primarily we're using machine learning and network biology to understand the mechanism of action of antibiotics and how resistance arise with the goal of boosting what we already had, with Regina we saw there was an opportunity to see if we could use deep learning to get after discovery.(02:55):And notably, as you kind of alluded in your introduction, there's really been a discovery void and the golden age of discovery antibiotics was in the forties, fifties and sixties before I was born and before you had the genomic revolution, the biotech revolution, AI revolution. Anyways, we got together with our two groups, and it was an unfunded project and we kind of cobbled together very small training set of 2,500 compounds that included 1,700 FDA approved drugs and 800 natural compounds. In 2018, 2019, when you started this, if you asked any AI expert should you initiate that study, they would say absolutely not, there's going to be two big data. The idea of these models are very data hungry. You need a million pictures of a dog, a million pictures of a cat to train a model to differentiate between the cat and the dog, but we ignored the naysayers and said, okay, let's see what we can do.(03:41):And we apply these to E. coli, so a model pathogen that's used in labs but is also underlies urinary tract infections. So it's a look to see which of the molecules inhibited growth of the bacteria as evidence for antibacterial activity and we could have measured and we quantified each of their effects, but because we had so few compounds, we just discretized instead, if you inhibited at least 80% of the growth you were antibacterial, and if you didn't achieve that, you weren't antibacterial zero in ones. We then took the structure of each molecule and trained a deep learning model, specifically a graphical neural net that could look at those structures, bond by bond, substructure by substructure associated with whatever features you look to train with. In our case, making for good antibiotic, not for good antibiotic. We then took the train model and applied it to a drug repurposing hub as part of the Broad Institute that consists of 6,100 molecules in various stages of development as a new drug.(04:40):And we asked the model to identify molecules that can make for a good antibiotic but didn't look like existing antibiotics. So part of the discovery void has been linked to this rediscovery issue we have where we just keep discovering quinolones like Cipro or beta-lactams like penicillin. Well, anyways, from those criteria as well as a small tox model, only one molecule came out of that, and that was this molecule we called halicin, which was named after HAL, the killing AI computer system from 2001 Space Odyssey. In this case, we don't want it to kill humans, we want it to kill bacteria and as you alluded, it turned out to be a remarkably potent novel antibiotic that killed off multi-drug resistant extensively drugs, a pan-resistant bacteria went after to infections. It was affected against TB, it was affected against C. diff and acinetobacter baumannii and acted to a completely new mechanism of action.(05:33):And so we were very excited to see how AI could open up possibilities and enable one to explore chemical spaces in new and different ways. We took them model, then applied it to a very large chemical library of 1.5 billion molecules, looked at a subset of about 110 million that would be impossible for any grad student, any lab really to look at that experimentally but we looked at it in a model computer system and in three days could screen those 110 million molecules and identified several new additional candidates, one which we call salicin, which is the cousin of halicin that similes broad spectrum and acts to a novel mechanism of action.Eric Topol (06:07):So before we go further with this initial burst of discovery, for those who are not used to deep neural networks, I think most now are used to the convolutional neural network for images, but what you use specifically here as you alluded to, were graph neural networks that you could actually study the binding properties. Can you just elaborate a little bit more about these GNN so that people know this is one of the tools that you used?Jim Collins (06:40):Yeah, so in this case, the underlying structure of the model can actually represent and capture a graphical structure of a molecule or it might be of a network so that the underlying structure itself of the model will also look at things like a carbon atom connects to an oxygen atom. The oxygen atom connects to a nitrogen atom and so when you think back to the chemical structures we learned in high school, maybe we learned in college, if we took chemistry class in college, it was actually a model that can capture the chemical structure representation and begin to look at sub aspects of it, associating different properties of it. In this case, again, ours was antibacterial, but it could be toxic, whether it's toxic against a human cell and the model, the train model, the graph neural model can now look at new structures that you input them and then make calculations on those bonds so a bond would be a connection between two atoms or substructures, be multiple bonds, interconnecting multiple atoms and assign it a score. Does it make, for example, in our case, for a good antibiotic.Eric Topol (07:48):Right. Now, what's also striking as you set up this collaboration that's interdisciplinary with Regina, who I know of her work through breast cancer AI and not through drug discovery and so this was, I think that new effort and this discovery led to this, I love the name of it, Audacious Project, right?Jim Collins (08:13):Right. Yeah, so a few points on the collaboration then I'll speak to Audacious Project. In addition to Regina, we also brought in Tommi Jaakkola, another AI faculty member and marvelous colleague here at MIT and really we've benefited from having outstanding young folks who were multilingual. We had very rich, deep trained grad students from ML on Regina and Tommi's side who appreciated the biology and we had very richly, deeply trained postdocs, Jon Stokes in particular from the microbiology side on my side, who could appreciate the machine learning and so they could speak across the divide. And so, as I look out in the next few decades in this exciting time of AI coming into biomedicine, I think the groups will make a difference of those that have these multilingual young trainees and two who are well set up to also inject human intelligence with machine intelligence.(09:04):Brings the Audacious Project. Now, prior to our publication of halicin, I was invited by the Audacious Project to submit a proposal, the Audacious Project is a new philanthropic effort run by TED, so the group that does the TED Talks that's run by Chris Anderson, so Chris had the idea that there was a need to bring together philanthropists around the world to go for a larger scale in a collective manner toward audacious projects. I pitched them on the idea that we could use AI to address the antibiotic resistance crisis. As you can appreciate, and many of your listeners can appreciate that we're doomed if we don't actually address this soon, in that the number of resistance strains that are in our communities, in our hospitals has been growing decade upon decade, and yet the number of new antibiotics being developed and approved has been dropping decade upon decade largely because the antibiotic market is broken, it costs just as much to develop an antibiotic as it does a cancer drug or a blood pressure drug.(09:58):But antibiotic you take once or maybe over the course of three to five days, blood pressure, drug cancer drug you might take for months if not for the rest of your life. Pricing points for antibiotics are small dollars, cancer drugs, blood pressure drugs, thousands if not hundreds of thousands. We pitched this idea that we can maybe turn to AI and use the power of AI to address this crisis and see if we could use our wits to outcompete the genes of superbugs and Chris and his team really were taken with this, and we worked with them over the course of nine months and learned how to make the presentations and pulled this together. Chris took our pitches to a number of really active and fantastic philanthropists, and they got behind us and gave us a good amount of money to launch what we have now called the Antibiotics-AI Project at MIT and in conjunction with it and also using funding from the Audacious Project, we've launched a nonprofit called Phare Bio which is French for lighthouse, so our notion is that antibiotics are public good that we need to get behind his community and Phare Bio, which is run by Akhila Kosaraju, she's the CEO and President, is the mission of which is to take the most promising molecules out of the antibiotics AI project and advance them towards the clinic through partnerships with biotech, with pharma, with other nonprofits, with nation states as needed.Eric Topol (11:18):Well, before I get to the next chain of discovery and as explain ability features, which we all like to see when you can explain stuff with AI, did halicin because of this remarkable finding, did it get into clinical trials yet?Jim Collins (11:36):It's being advanced quite nicely and aggressively by Phare Bio. So Phare Bio is in discussions with the Department of Defense and BARDA, and actually on an interesting feature of halicin is that it acts like a flash bomb in the gut, meaning that when delivered orally to the gut, it only acts briefly and very quickly in a fairly narrow spectrum manner as well, so that it can go after pathogens sparing the commensals. One of the challenges our US military face is one of the challenges many militaries face are gut issues when soldiers are first deployed to a new location, and it can disable the soldiers for three to four weeks. And so, there's a lot of excitement that halicin might be effective as a treatment to help prevent gut dysbiosis resulting from new deployments.Eric Topol (12:27):Oh wow. That's another application that I would never have thought of. Interesting, so you then moved on to this really big report in Nature, which I think this is now involving a transformer model as I recall. So you can explain the difference and you made a discovery from a massive, again, number of potential compounds to staph aureus resistant methicillin resistant agents that were very potent in vivo. So how did you make this big jump? This is a whole new structural class of antibiotics.Jim Collins (13:11):Yeah, so we made this jump, this was an effort led by Felix Wong, who's a really talented postdoc in my lab, and we got intrigued of to what extent could we expand the utility of AI and biology of medicine. As you can appreciate that, that many of our colleagues are underwhelmed by the black box nature of many AI models and by black box I mean that when you train your model, you then largely use it as a filter where you'll provide the model with some input. You look at the output and the outputs, what's of interest to you, but you don't really understand in most cases, what guided the model to make the prediction of the output that you look at and that can be very unsatisfactory for biology, interested in mechanism. It can be very unsatisfactory for physicians interested in understanding the underlying disease mechanism.(13:57):It can be unsatisfactory for biotech and drug discoveries that want to understand how drugs act and what maybe underlies meaningful structural features. So with Felix, we decided it'd be interesting if you could open up the box. So could you look inside the model to see what was being learned? We are able to open up, in this case actually, we primarily focused on graph neural nets. We now have a new piece we're just about to submit on transformers, but in this case, we could open up and look to see what were the rationales, what were the chemical substructures that the model was pointing to in each compound that was leading to the high prediction that it could make for a good antibiotic and these rationales we then used as hooks, I should notably say, that we were able to identify the rationales from these large collections using algorithms that would develop by DeepMind as part of their AlphaGo program.(14:51):So AlphaGo was developed by DeepMind as a deep learning platform to play and win go the ancient Asian board game and we used similar approaches called Monte Carlo Tree Search that allowed us to identify these rationales that we effectively then used as hooks and kind of organizing hooks on screens where you can envision or appreciate that most exposed screens give you one-offs. This molecule does what you want and silico screens are similarly designed with these rationales. We could use them as organizing hooks to say, ah, these compounds that are identified as making for very good antibiotics all have the same substructure and thus they likely in the same class and act in similar mechanism and this led us to identify five novel classes, one of which we highlighted in this piece that acts very effectively against MRSA, so methicillin-resistant staph aureus you alluded, which is probably the most famous of the antibiotic resistant pathogens that we even outside infectious are quite familiar with. It be devil's athletes, so NFL players are often hit with MRSA, whether from scraping their limbs on AstroTurf or from actually surgeries to say, for example, correct something at their knee. This new class had great efficacy in animal models, again, acting through a new mechanism.Eric Topol (16:12):Will you bring that forward like halicin through this same entity?Jim Collins (16:17):Yes. We've now provided the molecules to Phare Bio and they're digging in to see which of these might be the most exciting and interesting to advance clinically.Eric Topol (16:26):I mean, it's amazing because this area is so neglected. Maybe you can help explain, since we're talking about existential threats as we get more and more resistant antibiotics and the biopharma industry is basically not into this and it relies on the work that you've been doing perhaps or other groups, I don't know of any that are doing more than you. I mean, it's incredible to me. Is it just because of the financial aspects that there's no business in the life science industry?Jim Collins (17:03):It's an interesting challenge. So I've thought about it. I really haven't come up with a great solution yet, but I think you've got multiple factors at play. One is that I think all of us, every one of your listeners has lost someone to a bacterial infection, but in most cases you don't realize you lost them to a bacterial infection. It might be that your elderly relative went into the hospital with a condition but acquired hospital-based infection and died subsequently from that and happened quite quickly. Another cases, again, it's secondary. Notably, during the pandemic, one out of seven individuals hospitalized for Covid had a bacterial infection and 50% of those who died had a bacterial co-infection. And noted by going back to the Spanish flu of over a hundred years ago. It was as deadly as it was because we didn't have antibiotics and most of the folks that died had a bacterial co-infection.(17:56):So you have this in the backdrop, you then have that, nobody's kind of gotten behind it, so we don't have any major foundation addressing antibiotic resistance. There are no charity walks, there are no charity runs, there is no month, there is no color, there are no ribbons, there are no celebrity behind it, there's just not known so it hasn't captured the public's imagination. AThen you come with that, this backdrop of the broken market where I said shared, it's really expensive to develop a new antibiotic, but if you develop a new antibiotic, the tendency now will be to shelve it until it's desperate so now even the young companies that had developed and gotten an antibiotic through to approval often went bankrupt because the model, the market couldn't provide them with revenue to go after the next one or sustain their efforts. And so you have pharma biotech jumping out. I think we need two-pronged effort going forward. I do think we need nation states to come forward and get behind this, and I think we increasingly need philanthropists to come forward and go after it. As I share your term of existential threat, I think if you speak with most educated individuals, antibiotic resistance broadly, antimicrobial resistance will be on everyone's existential threat list but notably of that list, it's the cheapest one that can be solved.Eric Topol (19:09):Well, you're showing that you've got the most extraordinary candidates that have been found in decades. So that says a lot right there.Jim Collins (19:18):Important step, yeah. So I think we've got additional innovation needed in the models to address this, and until we have that address, then this interesting discoveries we and others are making will not get to patients. So we need to have that additional next step to close this gap.Eric Topol (19:32):Now, obviously this has relied on AI and the progress that's occurring in AI to enable some of your work. I am fascinated by the use of AlphaGo. Most times we hear about using AlphaFold2, but you actually use AlphaGo the original game DeepMind work but there also was the progress of from deep neural networks to transformer models and your ability now to basically exemplify what can be achieved in drug discovery using the progress in multimodal AI. Is this something that is making a difference for you and your group?Jim Collins (20:13):It is, it's huge. I think it's very early in terms of the introduction to these new tools extensively within drug discovery. Machine learning has been used for over two decades, both supervised learning and unsupervised learning. Now we're seeing groups coming in for the deep learning efforts. It's largely data-driven so in fact, with the exception of sequences, most of drug discoveries not yet big data in the big data phase, but it's beginning to change. It's truly been transformative for us, so we've used graph neural nets primarily for our discovery efforts. We're now beginning to incorporate language models as multimodal models along with the graph neural nets as well as to see to what extent pre-trained language models. For example, mobile form from IBM, which was trained on PubChem and the ZINC database could be fine-tuned with small amounts of training data, screening data from a resistant organism.(21:06):Third, and I made an indirect allusion already, we've been looking at using transformers and genetic algorithms in older form of AI tech for design of novel antibiotics so we've been now looking to see using fragments as a starting base, using trained models to build out novel antibiotics that can then be de novo designed. One of the big challenges in that space is how do you synthesize these molecules? So you have both the challenge of can you come up with a small number of steps that enable you to synthesize? And second is could you find somebody to synthesize them? And each of those remains very big challenges. My faculty colleague here at MIT, Connor Coley's probably one of the world leaders, easily, he's in using AI to calculate the synthesized ability of a molecule, but we still have gaps in that we don't have the community resources to make most of what we come up with.Eric Topol (21:58):Well, one of the features of large language models that David Baker at the Protein Design Institute exploited is its ability to hallucinate and come up with proteins that don't exist. Can you do the same thing in your design of antibiotic candidate molecules in a way that is not worrying about the synthesis, but just basically the hallucinatory behavior of large language models?Jim Collins (22:28):It's interesting, so yes and so David's work is marvelous and we're big fans and longtime friends of his work. Yes, so we've been driving these models truly to do de novo synthesis. So based on what has been learned, can you put together molecules that one's never seen before? We're doing it quite successfully. It becomes interesting from the hallucination in that it comes out really more of these models making stuff up and ours it's really more directing the hallucinations, right? Really looking to see can we harness the imagination of the models in order to move them forward in very creative design manners.Eric Topol (23:08):Yeah, I mean, I think most people have a negative connotation of hallucinations, but these are the smart variety potentially. This in many ways you could say there's so much crowded interest in the drug discovery AI world, but what you're doing now seems to be setting the pace in many respects for others to follow such remarkable advances in a short time. By the way, we'll link to that TED talk you gave in April 2020, where in seven minutes you went over what you're doing of course and who would've, and that was in 2020 that where you'd be three or four years later, and that was what you're going to do over the next seven years with seven new classes of new antibiotics. Now, before we wrap up, it isn't just that you're an AI antibiotic, you and your team antibiotic discover and doing compressing in time, what has taken decades that you're doing in months, but also you are a father of figure in the field of synthetic biology and I wonder if you, before we wrap up, can explain not only what synthetic biology is since a lot of people don't really know what that means, but how does that dovetail with your efforts in what we've been discussing?Jim Collins (24:33):Yeah, thanks. So synthetic biology is a relatively new field that's bringing together engineers with biologists to use engineering principles to model design and build synthetic gene networks and other molecular components that can be used to rewire and reprogram living cells and cell-free systems, endowing them with novel functions of a variety of applications. So the circuits, these programmable cells are impacting broad swats of the economy from food and water to health and sustainability of bioenergy to human health. Our focus is primarily human health and we've been advancing the idea that you can reprogram bacteria to detect and treat bacterial infections. So we've shown you can use this to go after cholera, we've shown you can use is to prevent antibiotic induced gut dysbiosis. We've also used synthetic biology to create whole new classes of diagnostics. For example, paper-based ones using RNA sensors for Ebola, for Zika and for Covid.(25:33):How it dovetails with what we talked about is that I think there's a great opportunity now to turn to AI to expand synthetic biology, both expanding the number of parts we have to re-engineer living systems as well as to better infer design principles that can be used to reprogram rewire living systems. We're beginning to advance, we're not yet at the SynBio AI project phase, but very early efforts and David's dominating the protein space and we and others are beginning to now movement to the RNA space. So to what extent can we create large libraries of RNA components, train language-based models, structure-based models that can both predict RNA structure more critically predict RNA function and as you know from your marvelous work and what's happening is that it's the exciting age of RNA of getting after RNA therapeutics, be it mRNA or CRISPR related and we still need to get better at our ability to design those therapeutics with certain functions in mind, and we think AI is going to help get us there faster.Eric Topol (26:34):Well, speaking of that, there was a paper this week in Cell by McCafferty and colleagues, and one of the sentences that struck me, we are standing on the cusp of a new era of biology, where the integration of multimodal structural datasets with multiscale physics-based simulation will enable the development of visible, virtual cells. This is yet another lineage or direction of where we're headed with AI, but this fusion of the advances that are occurring right now in biology with AI that extend in many different directions, it's so exciting and you are basically nailing it. I mean, you're putting points on the board, Jim, and I just have to say, I'm blown away by what you've been accomplishing in a time space that's so incredibly compressed.Jim Collins (27:40):Oh, well thanks. Well, you think back to the early days of molecular biology and physicists like Francis Crick and Max Delbrück played huge pioneering roles and then in the second wave in the eighties or so, you had other physicists like Walter Gilbert playing big roles. I do think physicists computer scientists are starting now to play big roles in this next phase where we need tools like AI in order to really grapple with and harness the complexity, both the biology and the chemistry that underlies living cells. They can kind of expand our intuitions both to understand and to really control these systems for good going forward.Eric Topol (28:15):Well, you're doing it and we're be cheering for the success of these drugs that you've come up with in the clinical trials as they go forward because they look so remarkably promising. You even highlighted ways that I wouldn't have envisioned where they could make a difference, so we'll follow your work, you and your colleagues with great interest. Thanks so much for joining,Jim Collins (28:37):Eric, thanks for having me. Enjoyed our conversation.******************************************************************************Thanks for listening to Ground Truths. Please share if you found this podcast informative.Full video interview will post here Get full access to Ground Truths at erictopol.substack.com/subscribe

Greg's background is in medicine, but he has been passionate about wine since his first sip of a vintage wine in Napa at age 16. He received his Master of Science in Medical Engineering and a Bachelor of Science in Nuclear Engineering from the Massachusetts Institute of Technology. I'm not a wine guy, but the history of why wine is bottled in glass and the size of the bottle is interesting. We discuss all of that and why Coravin solves many of the problems of storing wine after it has been opened.   Number One Tip: The best inventions come from meeting an unmet need. And you need to know whether you want to be an inventor or an entrepreneur.    Contact Information: DM him on X and Instagram: Gregatcoravin The Engineering Entrepreneur Podcast is produced by Scott Tarcy, President of CADdesignhelp.com. You can reach me at info@caddesignhelp.com.

In the first episode of Raising Biotech, Surani speaks with CEO and co-founder Jason Park of Empress Therapeutics, a Flagship Pioneering company that was unveiled in June 2023 with a $50 million financing.Surani speaks to Jason about his journey to co-founding Empress and the ideas behind Empress' scientific thesis of looking for small molecule drug leads "within the human body." He also talks about how the company is deciding which of its 15 drugs candidates to take into the clinic while it also talks to potential development partners. Jim Collins, Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT, gives his take on Empress' unique technology, its use of AI in a different way to competitors, and its advantageous position to discover drugs "faster, better and cheaper." Dr Leon Henderson-MacLennan, medical advisor and co-founder of consultancy firm, InThought also gives his views on the various targets that Empress' compounds are hitting and where the company could add value amidst the current treatment paradigm of small molecules and biologics.Jason and expert guests also weigh-in on questions around the platform's potential to treat Alzheimer's disease and other neurological indications given current problems penetrating the blood brain barrier with biologics. All three guests also discuss the potential impact of the US Inflation Reduction Act (IRA) on incentives for small molecule development.Timestamps:00:55 - Jason gives Empress' elevator pitch on the Chemilogics platform03:20 - Rewinding the clock to Jason's back story04:28 - The business model of VC firm Flagship Pioneering05:33 - What sparked the idea for Empress' scientific thesis08:05 - 2017 up to present - datasets to 15 drug leads09:35 - Jim (MIT) gives his take on Empress' platform11:50 - Can Empress' thesis impact the clinical trial path and timelines?14:03 - Which indications and therapeutic areas are on the table?15:55 - Leon (InThought) speaks on drug targets enzymes, cytokines, GCPR and ion channels21:06 - Potential for Alzheimer's disease with blood brain barrier penetration22:53 - Impact of Inflation Reduction Act (IRA) on small molecule developers25:44 - Empress' future steps to prioritize drug candidates and partnership talks28:11 - Future visions for the companyFor any comments, questions, feedback or suggestions you can connect directly with Surani Fernando on LinkedIn or email: raisingbiotech@gmail.comMusic composed by: Yrii Semchyshyn (Coma Media) Hosted on Acast. See acast.com/privacy for more information.

Ellen Roche is an associate professor of mechanical engineering and the associate head of the Department of Mechanical Engineering at MIT. Her research team develops new devices and therapeutic strategies for repairing the heart and other tissues. Here, she speaks with MIT President Sally Kornbluth about her work, the advantages of taking a nonlinear route to one's chosen career, and the importance of saying "yes" to unexpected opportunities.Links:Ellen RocheTherapeutic Technology Design and Development LabVideo: Patient-specific, 3D-printed, soft-robotic heartsDassault SystèmesInstitute for Medical Engineering and ScienceTimestamps:(03:35) - Potential for 3D-printing hearts(08:14) - Hydrogels(17:33) - On AIShow notes and transcript:https://news.mit.edu/podcast/podcast-curiosity-unbounded-episode-6-healing-ailing-heartJoin the mailing list or send us feedback:https://eepurl.com/ixPQPA

Dr Sam John, a senior lecturer in neural engineering at the University Melbourne, joins our hosts to talk about his work with a group of biomedical engineering students to develop gaming consoles for people with cerebral palsy, and looking generally into adapting existing gaming controllers to make them more accessible for people who are differently abled. They speak about prototypes they've developed for this purpose, as well as the commercial possibilities of these developments.The hosts also talk about the updates in AI regulations globally, local changes to emergency mobile roaming, and the results of the first lawsuit against self-driving cars.Hosted by Dan Salmon, Dan Morganti and Ash Keller.

 Dr. Christoph Guger, hat Elektrotechnik in Linz und Baltimore studiert und unmittelbar nach seiner Dissertation über Brain-Computer Interfaces und Neurotechnologie 1999 das international erfolgreiche Unternehmen g.tec Medical Engineering gegründet. Brain-Computer Interfaces (BCI) sind Gehirn-Computer-Schnittstellen, die Gehirnaktivität messen und analysieren, um damit andere Geräte anzusteuern.René Neubach und Dominik Flener sprechen mit Mastermind Christoph Guger über die aktuellen Entwicklungen, Nutzen und Chancen rund um das spannende Thema Brain-Computer Technologie und Neurotechnologie im Healthcare-Bereich.In diesem Zusammenhang erzählt Christoph Guger über die vielfältigen Anwendungsmöglichkeiten: Wie vollkommen gelähmte Personen kommunizieren können, bei Wachkomapatienten mittels Brain-Computer Technologie festgestellt werden kann, ob sie Gespräche verstehen und bei Schlaganfall-Rehabilitation dank Neurotechnologie, Hand- und Gangfunktion auch Jahre später wieder hergestellt werden kann. Die Forschung rund um BCI boomt, aktuell forschen viele 100 Unis weltweit daran und Biomedizinische Technik ist heutzutage eines der wichtigsten Studienfächer geworden. Außerdem spannende Themen dieser Folge: die Rolle von BCI in der Automobilindustrie, für Piloten sowie in der Spieleindustrie und rund um Artificial Intelligence. Zudem verrät Christoph Guger sein Erfolgsgeheimnis beim Recruiting und der Kommunikationsstrategie von g.tec.Im abschließenden Ausblick spricht Christoph Guger über spannende Anwendungsmöglichkeiten, bei denen sich zukünftig viel tun wird, wie Spielentwicklung, Neuromarketing und Security.Timestamps03:45 Wer ist Christoph Guger? 05:19 Was sind Brain-Computer Interfaces (BCI)?05:36 Anwendungsbeispiele 06:54 Rolle von g.tec und Österreich in diesem Bereich der Forschung und Entwicklung07:55 Unternehmensbereiche und Kunden von g.tec08:10 Sparte Forschung & Unis08:50 Sparte Medizinprodukte: Recoverix09:24 Sparte Endanwender: Unicorn Hybrid Black und Hackathon13:55 Wie bestimmte Gedanken vom BCI herausgefiltert werden können18:39 BCI als Möglichkeit um Pflegepersonal zu entlasten?21:31 Erfolgsquoten von Recoverix bei Schlaganfall oder Multipler Sklerose24:47 Therapiekosten und Zusammenarbeit mit den Kostenträgern25:50 Vertriebsmodell: g.tec-Standorte international und lokale Vertriebspartner27:45 Franchise-Partner weltweit Einzelpersonen (Ärzte, Physiotherapeuten) Rehazentren Unternehmer, die eine bestehende Firma erweitern wollen32:10 andere Anwendungsgebietebei Autoherstellern - Optimierung der Fahrgastzelle  bei Piloten - Messung der kognitiven Belastung33:50 Wie BCIs helfen können, Dinge herauszufinden36:09 Sinnvolle und sinnlose Varianten von BCI und können BCI und AI zusammenspielen? 37:12 Alzheimer Früherkennung38:04 Chat GPD39:02 Wie gut oder sinnvoll ist AI?39:35 Personalsuche über BCI Spring School mit 16.000 Teilnehmern42:43 Recruiting-Prozess via klassischen Interview statt BCI43:15 Homeoffice-Policy und reelles Büro44:19 Außenkommunikation und Awareness LinkedIn und wissenschaftliche Konferenzen PR, Medien, Mundpropaganda von Patienten Therapiezentren: LinkedIn, Mundpropaganda durch Patienten, Google47:47 Was auf LinkedIn gut funktioniert: Veranstaltungs-Infos und Erklär-Infos bzw. Videos50:50 Entscheidungsprozess: Touchpoints mit Kunden, bis ein Kauf stattfindet 52:35 Ausblick: Zukünftige Anwendungsfälle (Medizin-Bereich, Spielentwicklung, Neuromarketing, Security)54:10 Kritische Aspekte bei Neuromarketing: Genauigkeit & Quantifizierung Visit us on: LinkedIn | Facebook | InstagramRené Neubach: LinkedIn | Facebook | InstagramDominik Flener: LinkedIn | Facebook | Instagram 

During a session at Sanders Theatre, Harvard Medical School, on “Memory, Consciousness, and Coma” on May 14, Emery N. Brown, MD, PhD, Warren M. Zapol Professor of Anesthesia at Harvard Medical School and at Massachusetts General Hospital, Edward Hood Taplin Professor of Medical Engineering and Professor of Computational Neuroscience at MIT; and Nicholas D. Schiff, MD, PhD, The Jerold B. Katz Professor of Neurology and Neurosciences, Weill Cornell Medical College,New York, seek Sadhguru's inputs on various aspects of anesthesia, the brain and science. Conscious Planet: https://www.consciousplanet.org Sadhguru App (Download): https://onelink.to/sadhguru__app Official Sadhguru Website: https://isha.sadhguru.org Sadhguru Exclusive: https://isha.sadhguru.org/in/en/sadhguru-exclusive Inner Engineering Link: isha.co/ieo-podcast Yogi, mystic and visionary, Sadhguru is a spiritual master with a difference. An arresting blend of profundity and pragmatism, his life and work serves as a reminder that yoga is a contemporary science, vitally relevant to our times. See omnystudio.com/listener for privacy informationSee omnystudio.com/listener for privacy information.

During a session at Sanders Theatre, Harvard Medical School, on “Memory, Consciousness, and Coma” on May 14, Emery N. Brown, MD, PhD, Warren M. Zapol Professor of Anesthesia at Harvard Medical School and at Massachusetts General Hospital, Edward Hood Taplin Professor of Medical Engineering and Professor of Computational Neuroscience at MIT; and Nicholas D. Schiff, MD, PhD, The Jerold B. Katz Professor of Neurology and Neurosciences, Weill Cornell Medical College,New York, seek Sadhguru's inputs on various aspects of anesthesia, the brain and science. Conscious Planet: https://www.consciousplanet.org Sadhguru App (Download): https://onelink.to/sadhguru__app Official Sadhguru Website: https://isha.sadhguru.org Sadhguru Exclusive: https://isha.sadhguru.org/in/en/sadhguru-exclusive Inner Engineering Link: isha.co/ieo-podcast Yogi, mystic and visionary, Sadhguru is a spiritual master with a difference. An arresting blend of profundity and pragmatism, his life and work serves as a reminder that yoga is a contemporary science, vitally relevant to our times. See omnystudio.com/listener for privacy informationSee omnystudio.com/listener for privacy information.

About 54 million Americans and 936 million patients globally suffer from sleep apnea and 80% of cases go undiagnosed. Today's guest is fixing that problem.Chris Fernandez co-founded EnsoData in June 2015 to use AI to make sleep studies more efficient, cost effective, and accurate.Since then, he and the team have raised more than $30M from an exceptional group of investors including Zetta Venture Partners, M25 Ventures, and Inspire Medical Systems.Chris received his bachelors and masters degrees from the University of Wisconsin-Madison in Biomedical and Medical Engineering. He also wrote one of the most thoughtful perspectives on the entrepreneurial journey when he handed over the reigns to new CEO Justin Mortara last November. At 8,200 words, it may also be one of the longest.Listen and learn...What led Chris to care about solving sleep problemsHow EnsoData overcame being "a solution in search of a problem"How AI and machine learning can be applied to sleep apneaHow being incubated by Y Combinator helped launch EnsoDataHow to use brainwaves to train AI models to diagnose sleep issuesWhen we'll get "smart rooms" that adjust the environment to optimize for healthy sleepHow Chris and the team control for the impact of AI biasHow to improve the quality of your sleep... from an expertWhat led Chris to replace himself as CEOReferences in this episode...Gordon Wilson, Rain Neuromorphics CEO, on AI and the Future of WorkWhy We Sleep by Matt WalkerStanford Professor Dr. William Dement and the origins of sleep science

Meet Elazer EdelmanElazer R. Edelman, M.D., Ph.D., is the Edward J. Poitras Professor in Medical Engineering and Science at MIT, Professor of Medicine at Harvard Medical School, and Senior Attending Physician in the coronary care unit at the Brigham and Women's Hospital in Boston. Key Insights:Dr. Edelman works at the intersection of the physical sciences and medicine to improve healthcare. Key Intersections. Dr. Edelman believes that clinical work, scientific research, and engineering must all come together to keep the medical profession on track.Explaining and Receiving Feedback. Physician-scientists have an obligation to explain their methods and then to listen carefully to feedback to ensure widespread understanding.How to spur Innovation? Create communities where people feel safe and secure saying that they don't know—and then let them investigate.  This episode was made possible by our partnership with Edwards Lifesciences. Relevant Links:Read more about Dr. EdelmanLearn about the Brigham and Women's Hospital 

FR. KEVIN FITZGERALD, SJ, PHD, PHD​Healing Post-Covid Healthcare by Greater Integration of the Humanities and Ethics into Healthcare EducationKevin T. FitzGerald, S.J., Ph.D., Ph.D., is the John A. Creighton University Professor and chair of the Department of Medical Humanities in the School of Medicine, at Creighton University. He received a Ph.D. in molecular genetics, and a Ph.D. in bioethics, from Georgetown University. His research efforts focus on the utilization of the Humanities in medical education, on the investigation of abnormal gene expression in cancer, and on ethical issues in biomedical research and medical genomics. He has published educational, scientific, and ethical articles in peer-reviewed journals, books, and in the popular press.Fr. FitzGerald has given presentations nationally and internationally, and has often been interviewed by the news media, on such topics as human genetic engineering, cloning, stem cell research, and personalized medicine. He is a founding member of Do No Harm, and a member of the Genetic Alliance IRB. In addition, he has been a Corresponding Member of the Pontifical Academy for Life since 2005.ABSTRACTThe Covid pandemic greatly exacerbated deep flaws in our healthcare institutions and educational programs. To help heal these deep flaws, Creighton University is intentionally and intensively integrating the humanities and ethics into all its health professions programs, both undergraduate and graduate. Though early in this process, evidence is already manifesting the value this integration is having with our students and faculty, and, hence, with those they care for and work with. A brief introduction and summary of this effort will be presented in hopes of generating further discussion of how all of us can create a healthcare education program adequate to meet the enormous financial, social, moral and spiritual challenges healthcare faces today.KEVIN POWELL, MD, PHD The Application of Faith and Reason to Clarify Truth in Medical CareKevin Powell, M.D. Ph.D. FAAP, is a retired pediatrician who specialized in the care of hospitalized children. Prior to medical school he worked as a chemical engineer in industry and academia, earning a Ph.D. in Medical Engineering from a joint program of Harvard Medical School and the Massachusetts Institute of Technology. Alongside clinical care, for 18 years he served on or chaired hospital ethics committees and was a clinical ethics consultant. His last academic position was on faculty at Saint Louis University and Cardinal Glennon Children's Hospital. He is Lutheran.ABSTRACTMedical knowledge is constantly evolving and occasionally advancing. Most of what I was taught in medical school became obsolete, contradicted, or was shown to have always been flat out wrong by the time I retired. The practice of clinical medicine requires continuous adoption, improvement, refinement, and frequently rejection of new knowledge. That knowledge needs to be adapted to function within evolving moral norms and cultural values. The search for truth is ever-present. The encyclical Fides et Ratio says “Faith and reason are like two wings on which the human spirit rises to the contemplation of truth.”REV. FR. NICANOR PIER GIORGIO AUSTRIACO, O.P.An Ethical Assessment of Puberty Blocking Hormonal Treatments for Gender Dysphoria in Children​Fr. Nicanor Austriaco, OP is a Professor of Biological Sciences and a Professor of Sacred Theology at the University of Santo Tomas in the Philippines. He completed his Bachelor of Science in Bioengineering at the University of Pennsylvania, summa cum laude, and then earned his Ph.D. in Biology from M.I.T. where he was a fellow of the Howard Hughes Medical Institute (HHMI). He earned a Doctorate in Sacred Theology (S.Th.D.) at the University of Fribourg in Switzerland, in 2015. His first book, Biomedicine and Beatitude: An Introduction to Catholic Bioethics, was published by the Catholic University of America Press in 2011. It was recognized as a 2012 Choice outstanding academic title by the Association of College and Research Libraries.ABSTRACTShould puberty blockers be used to treat gender dysphoria (GD) in children? For activists promoting transgender rights, the answer to this question is a clear yes. However, several recent reviews of the medical literature have concluded that there is insufficient evidence to assess the long-term effects of hormone treatment on prepubescent children who experience GD. Therefore, in the absence of a robust risk-benefits analysis, it is unethical to promote this controversial medical intervention. It is not surprising that in Norway, Sweden, and Finland, public health officials are warning that for teens with adolescent-onset dysphoria, the use of these puberty blocking drugs may do more harm than good.

Links from the show:* The Age of Scientific Wellness: Why the Future of Medicine Is Personalized, Predictive, Data-Rich, and in Your Hands* Connect with Nathan* More about Thorne* Never miss an episode* Rate the showAbout my guest:Dr. Nathan Price is Chief Scientific Officer of Thorne HealthTech (NASDAQ: THRN) and author of The Age of Scientific Wellness (Harvard Press/Belknap). Previously he was CEO of Onegevity, an AI health intelligence company that merged with Thorne prior to its IPO in 2021. In 2019, he was named as one of the 10 Emerging Leaders in Health and Medicine by the National Academy of Medicine, and in 2021 he was appointed to the Board on Life Sciences of the National Academies of Sciences, Engineering, and Medicine. He spent much of his earlier career as Professor and Associate Director of the Institute for Systems Biology (now on leave), co-director with biotechnology pioneer Lee Hood of the Hood-Price Lab for Systems Biomedicine, and is Affiliate Faculty at the University of Washington in Bioengineering and Computer Science & Engineering. He is a Camille Dreyfus Teacher-Scholar, received the 2016 Grace A. Goldsmith award for his work pioneering ‘scientific wellness', was a co-founder of Arivale, received a Healthy Longevity Catalyst Award from the National Academy of Medicine in 2020, and is a Fellow of the American Institute for Biological and Medical Engineering. Get full access to Dispatches from the War Room at dispatchesfromthewarroom.substack.com/subscribe

(2:25) - Episode 75. Dandelion Inspired Sensors & Microscale Robotic Cilia(5:10) - Episode 99. Ensuring AI Works With The Right Dose of Curiosity(9:40) - Episode 88. AI For Making AI More Creative(15:36) -Episode 90. Wearable To Detect Sleep Apnea(21:49) - Episode 87. Sustainable Hydropower(22:38) - Episode 93. Algorithms predict sports teams' moves with 80 percent accuracy

This episode of Longevity by Design discusses topics related to regenerative medicine—senescent cells, biomaterials, arthritis, immunology, and more.In this episode of Longevity by Design, our hosts, Dr. Gil Blander and Ashley Reaver, MS, RD, CSSD, are joined by Dr. Jennifer Elisseeff. Dr. Elisseeff holds a PhD in Medical Engineering and has conducted many interesting studies relating to tissue engineering and the immune system. Tune in as Dr. Elisseeff discusses the latest science in the field. For science-backed ways to live a healthier longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast

Join us as we look at how medical engineering is helping save lives from vaccines to equipment. We also talk to Professor Gregoire Courtine who is a neuroscientist creating technology that could cure paralysis!See omnystudio.com/listener for privacy information.

(5:55) - Wearable To Detect Sleep ApneaEpisode 90 was brought to you by Duro, the PLM platform behind some of Farbod & Daniel's favorite hardware products. Click here to learn more about Duro and here to check out the Eight Sleep case study discussed in this episode.

(1:05) - Machine Learning Understands the Human Gut(15:43) - A  Major Step Forward in Organ Biofabrication--As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.To learn more about this show, please visit our shows page. By following the page, you will get automatic updates by email when a new show is published. Be sure to give us a follow and review on Apple podcasts, Spotify, and most of your favorite podcast platforms!

When you think of the future of clean energy, wind and solar might be the first things that come to mind. But when the wind doesn't blow and the sun doesn't shine, the need for alternative sources of power becomes apparent. From advanced geothermal to nuclear fusion, up-and-coming advancements may deliver a future of abundant, clean energy. One of the most ambitious ideas is space-based solar: orbiting solar panels that can beam energy to the Earth from space. Is this a viable energy solution ... or a sci-fi pipe dream? To find out more, I'm joined by Ali Hajimiri. Ali is the Bren Professor of Electrical Engineering and Medical Engineering at the California Institute of Technology, as well as Co-Director of the Space-Based Solar Power Project at Caltech.

Ali Hajimiri is the Bren Professor of Electrical Engineering and Medical Engineering at the California Institute of Technology. He is also co-director of the Space Solar Power Project, which is developing technology capable of generating solar power in space and beaming it back to Earth. Hajimiri and colleagues are designing solar arrays composed of hundreds of small photovoltaic tiles that would be linked together to form larger modules, and then those modules — flying together in formation like a school of fish — would form a hexagonal power station in space. These flexible arrays would be rolled up when launched and unfurl at their orbital destination.In this inaugural episode of Faster, Please! — The Podcast, Ali tells me about how space-based solar works, what problem it solves, and how long we'll have to wait before we see orbiting power stations in the sky. For more, check out my recent 5QQ chat with Ali. Below is a lightly edited transcript of our conversation.Pethokoukis: Space-based solar — putting solar panels in space and beaming the energy to Earth — seems like a beautiful, elegant solution. Why is it a good idea? What problem is it solving?Hajimiri: So the primary problem that it solves is being able to get around the days and nights, the cycles of the weather, the cloudy days, and all those things — and having dispatchable power where you need it, when you need it, and as much as you need.An advantage over ground-based solar?Correct. And the other benefit of it is that essentially you can have these systems in space for a long time, and you can route it the way you want. You can actually distribute the power; you can break it up into smaller pieces. You can say, “I want to send 20 percent to New York, 30 percent to LA, and 40 percent to, I don't know, Seattle.”Wouldn't these panels sometimes be in the darkness, on the night side of the Earth? So how would they work?It depends on which orbit you put it in. If you put them in geosynchronous orbit (or something near geosynchronous) you are basically in the sun for most of the time, except for 20 minutes on the equinoxes. Most of the time you're not eclipsed, because you're so far away that the shadow of Earth is so small. And because of the inclination of the Earth, because it's at an angle, you would get eclipsed for 20 minutes on each one of those.And as it's transferring power down, it doesn't have to be directly over the collection station, right? It can be at an angle?It doesn't. That's the beauty of it. Because it's a very large array, it redirects the energy. You can electronically steer it. It does not even need mechanical steering. So you can actually create a focal point of energy where you need, where your recovery of energy occurs. And you can move that very rapidly — on the scales of nanoseconds, extremely fast — from one place to another.Does it require new technology to distribute that power? Or is that basically using current technology?On the ground, we have what we call “rectennas,” which is basically rectifying antennas. These are another array of antennas that are very plain, very flat. I mean, if this were not radio, I would've had demonstrations of these things to show you how they look. But these are like thin sheets of material, like printed circuit boards that go in your computers and things of that sort, that sit on the ground. They collect the energy, they convert it to DC power, and then that's converted to AC. And then at that point, you can plug it in to connect to your network — essentially to your distribution line, the same power distribution line that you use. You can even envision putting this next to photovoltaic solar [panels] that are out there, or any other kind of power plant. It could be any kind of power plant, and you just connect to it and add and augment the power that you generate with these.So you can basically bolt this onto the existing power system?Yes. I mean, once you are on the ground station, once you go get past the rectenna and the conversion to AC, then that's basically compatible with all the other AC network.Solar power is becoming cheaper, and the land area we would need to cover with solar panels to power the whole Earth is smaller than you'd think. But traditional solar relies on storage at night when the sun isn't shining. But what you're suggesting wouldn't be reliant on batteries. Is that right?What we do allows you to send the power where you need at the time you need — and you can even break it up into different proportions. But the other thing that it does is that, since you have it 24/7, pretty much you don't need the storage, which is a big challenge.The other thing is that there are places that don't have the power infrastructure. A good analogy to this is cell phones versus landlines. Thirty years ago, there were places in Africa that didn't have landlines. In Sub-Saharan Africa today, there are these same places that still don't have landlines, but there they have leapfrogged to cell phones.So this way, you can actually get to places that don't have power. You can think about the Arctic Circle — you can think about a lot of places, remote islands and things of that sort — that may not have power infrastructure. And this way you can enable it when you need to have the power over there.This is not a new idea. It's an idea from about 80 years ago that you're attempting to turn into reality. I wonder if you could spend a minute or two talking about what you're doing.It is an idea that I think the earliest rendition, that I know of, is in a short story by Asimov, as many ideas are. But you know, what's different is that the technology didn't exist for doing these kinds of things in space. I mean, it sounds like a good idea, but it's also a very challenging idea in many different ways. One is that, when you put things in space, things are expensive — you pay dollars per gram. That's extremely expensive for things that you put in orbit. So one of the key parts of making this happen is to make it lightweight.The other thing is that these array elements, making it with large arrays, were not very practical up until the point where we are in integrated circuits — the same chips that go into our computers and phones. The same technology is now what we are using to make these incredibly large arrays that are very lightweight, because these are very small and lightweight.And then now, on top of it, we are making them flexible, because the way to deploy something that's of that magnitude is to roll it, then deploy it, and then unroll it. You can think about this like a sheet. These are like sails that you open up in space. Now, the technology to enable that integrated circuit, the packaging and all those things, did not really exist until recently. And that's why we came up with a new architecture for doing it, and that allows us to do the original renditions of this idea.The thinking was that we have the solar panels, and we aggregate all of the power. We have this giant antenna that points to Earth and then sends it. And in that case, you would be pointing to one direction, and you couldn't move it around because it was mechanically pointed. And if you wanted to reorient it, you have to mechanically reorient that antenna and point it in a different direction. We are doing it all electronically. So we have this very thin, very flat sheet that transmits the energy. Because of the coherent addition of all these billions and billions of sources — it's like an army of ants.So a swarm? A solar swarm?Exactly, exactly. So we've gone from the old mindset, which was what I describe as a big elephant, as opposed to an army of ants. I mean, each one of them is capable of doing different things, but because of the swarm nature, you can actually make it very lightweight and spread out.How old is the project that you're working on at Caltech?We've been working on this for close to eight years now — seven or eight years actively. We've been working on the power transfer part of it — the part that I'd been working on even before this project, which is what led to this project — for like 10 or 12 years. Wireless power transfer for both terrestrial, as well as space-based applications.And the powerless transfer is converted from sunlight into lasers? Microwaves? What?It's microwaves. It's radio frequencies, essentially microwaves. Then you transmit it, and then you recover that on the ground.Whenever I hear about any space project, I always think, “Well, was this possible before SpaceX? And is the reason we're talking about it because of that decline in launch costs?” Does your project depend on that, or is it just a fantastic enabler of it?I would say it's one of the four or five enablers that converged to make this closer to something that can actually be done. Definitely, SpaceX is a catalyst in lowering the barrier for space enterprises — anything that you want to do, non-governmental stuff, smaller projects — SpaceX and alike. I mean, there are other places like Blue Origin, things like that.So people are trying to do that. They are trying to level the playing field so that more entrepreneurs can get into it. Now it can be in academia, industry, or anywhere else. And that plays a role. And again, there are all these other technologies and architectural changes that also enable us. So I would say that's definitely one of the four or five catalysts that had to come together to make this happen.I've seen a video of you describing how there are small wafers that add up into bigger panels which are arranged into this giant array. Each one would be like a power plant in space. How big would each of those be?Yeah, that's a good way to think about it. Each one of these power plants, you can think about them on the order of a kilometer by kilometer, or about a mile by a mile. So that is like a square mile or square kilometer. Something in that range. It depends on the orbit you choose and the size of the ground station. There's a little bit of a tradeoff. You can make it larger in space and smaller on the ground, or smaller in space and larger on the ground. So there's that trade off you can play with. But yeah, it's about a square kilometer or square mile in space, each one of them.And how much power could that theoretically generate back on Earth?So somewhere between like several hundred megawatts to a gigawatt, depending on the angles and things like that. It's a substantial amount of power.How would that compare to a nuclear reactor?It would be comparable. And it can be even higher than that in some cases, depending. The other interesting thing I should say about comparing to these other kinds of generators is that, since it's a modular system — this is actually a formation flying of satellites; each one of the modules is about 20 to 60 meters, depending on different designs for different orbits; they are formation flying in close proximity to each other — and this means that if one of them fails, you can actually replace it without having to replace the whole thing. So it's very modular. You can actually have robustness because of that.I think when they had to repair the Hubble Space Telescope, it was a pretty big deal.Yes.And I'd hate to think it would be as involved with fixing each of these panels. All we'd be doing is space walks.Exactly. That's an excellent point because the way we've designed them, one of the key elements is the cost structure of these modules. It has to be economical at the end of the day, because we are using the same silicon technology that's used for all these electronics — and all the other stuff we're making at low cost. So the idea here is: For that component, we just decommission it, let it burn in the atmosphere and just put a new one in there. We don't have to replace components. It's just like a new satellite that's put in the orbit, and the other one is just decommissioned. And the cost structure allows for that.Would you envision this as just one arrow in the quiver? Or do you view this as something where we could get substantially all our power from space? What are sort of the potential and limitations?I think, like any other technology, if it's successful, it'll be phased in. You can't really do it all at once. Now, as more and more of these stations are going to be put in space, then you can see how this will respond to the system. But my anticipation is that it would definitely be filling in the gaps in the baseline.So, for example, if you look at the load line that the power generation has today on the Earth, it has changed because of the photovoltaics, quite interestingly. They had this duck — they call it the duck curve — because in the middle of the day, there's lower demand. The way it changes in the early afternoon, it goes up, peaks, and then comes back down and kind of looks like a duck.But the interesting thing is, now photovoltaics have kind of brought up the middle of the duck. So they've brought up this middle gap that they had. And then now it's gotten to a point that, at some points, the bulk price of power is actually negative during the day. And what this does is it allows you to fill in the gaps where you need it. So for example, you could have most of your power being transmitted to New York in the afternoon, but three hours later, you can shift that power to LA, for example.I think one thing people might say is, “We're already worried about too many Starlink satellites in orbit. These are much, much bigger! I mean, you would be able to see these from the Earth.” What do you make of that concern?So, there are different aspects to this. Is it mostly a concern about, for example, space junk and getting crowded and all those things?There's the space junk concern. There are also just these sort of astronomical concerns, that it would be hard to do astronomy. And more sort of aesthetic concerns.The aesthetic aspect, I can't talk to. I guess the beauty is in the eyes of the beholder. But the astronomy aspects: Again, there are obviously going to be windows, and there are going to be the times that this system passes overhead. But just to think about things, the area that is out there at 36,000 kilometers, which is the geosync, is actually 36 times larger than the area of the entire surface of the planet, including all of the water and all the oceans and everything. If you take that area, it's a much bigger sphere. So there's a lot more room, if anything, out there compared to other things that we make. So I'm not too concerned about that.There are also people who think about, “Is it going to cause interference?” and all those things. And those are the kinds of things that we've learned how to deal with in radio systems. We have many different radio systems working concurrently and seamlessly, and we don't seem to have problems with that — like Wi-Fi and 5G and this and that. And you have Bluetooth, and all of these things seem to be working together. And the main reason is that we've learned how to do it in that respect.There's also another set of concerns some people raise. “It's a health concern. Is it going to fry birds flying overhead?” And the answer to that is actually interesting, because the answer is that the energy density that anything, even in that beam spot, will get is comparable to what you get from standing out in the sun — except for the fact that it's what we call non-ionizing radiation as opposed to the sun, because it has UV and all those things that can actually change the molecules and the chemistry. So they can cause cancer (UV does), but radio frequencies don't. All they can do is generate heat. The benefit of this thing is that with that power level, you'd recover probably close to three times, three to three-and-a-half times, more than what you recover from photovoltaics. And you can have it during the day or night.I was recently reading a big report from Citigroup about the space economy, and they went into some detail about space-based solar. That's the first time I remember reading Wall Street research about that technology. At this point, is it still so early that you're not getting much private sector interest?First of all, I can tell you that there has been a tremendous amount of interest. I mean, especially recently, over the last couple of years, we've seen a lot more. And partly I think it's because of the fact that the technology … I mean, 10-20 years ago, it was not really realistic because of the cost structure, the complexity of tech technologies, and all those things. But now people are starting to see the pathway. So we've had a lot of interest from various places. And it's kind of growing exponentially in a way, recently.So I'm anticipating seeing a lot more of that investment. In fact, we've been approached by several investors in this regard, too. But it'll take time. It's not a short-term project. It's not an app that we can start today and have a first prototype working in a few weeks or months. We've been working on this for quite a while, and it has to continue on. We, in fact, are going to have a launch sometime soon, to have a first demonstration of some of the key components of the technologies that we are launching.The Chinese seem pretty interested in this technology.They are. And it's interesting. A lot of this thing has happened in part because of these new technologies that have been developed at Caltech and at other places that made it possible. So people are taking another look at it. There was this old kind of mindset about it, and this new mindset has renewed interest in it, because of these things. Yeah, the Chinese are interested. The United Kingdom is very interested in this. The Japanese are very interested in this. There are a lot of other efforts in other places — India is actually even interested in it. So we've actually seen a lot of interest all over the world, in this area.Is there something you need government to do or to stop doing at this stage in the development of the technology?A great question. One is, in terms of investment, definitely. These are the kind of things that, to get started, you need a big entity like government to put investment in it — in terms of research and development — because the barrier to entry is pretty large, regarding the amount of initial investment. Of course, the return eventually is going to be large, too.That's important also from a regulatory perspective. It's important for government in general — about the technologies related to wireless power transfer, both terrestrial and space — I think the government needs to be more proactive in terms of allowing it to flourish and not getting in the way. With everything new that comes in, there of course needs to be a thoughtful discourse about it. But if it gets to a point of becoming too much of an impediment to innovation and progress, then that would not be a good thing.So I think allowing these technologies to flourish — in terms of spectral allocations and other things of that sort — would be a good thing to continue to do.Are there key, deal-breaking technological challenges that you still need to solve? There are. I mean, it is fair to say that not all the technical challenges have been solved, but the pathway has become more clear over the last several years in terms of at least how we go about solving them. It's sometimes the unknown unknowns that get you at the end of the day. But we have more of the things that we know that we need to figure out. And I think we have a clear pathway.But in general, nobody has built a coherent structure of this magnitude anywhere — not even on Earth, let alone in space. So for example, that analogy that I used earlier: If you have an army of ants, you want the ants, that are like a mile apart, to be synchronized within a few picoseconds (and a picosecond is one-trillionth of a second).So the timing accuracy of that — that kind of thing … We have solutions; we are working on things. It's a combination of various advanced technologies that allows us to get this kind of timing synchronization. But those are the kind of challenges that we're trying to overcome and solve when you go to this scale. And it is something that has emerged because we've solved the other problems. Now we are at the point to say, “Okay, well, now we are scaling it up. How do we do these things?” And we need to solve these problems.How long until space-based solar arrives? Are we talking the 2030s? The 2040s?I'm more on the optimistic side, I guess. I think probably by the end of the 2020s, you will have some demonstration, some power transfer demo. We are going to have to show it soon. We are going to have some technology demonstrations.But if you want to have a substantial amount of power transferred, probably before the end of this decade. It would probably not provide a whole lot of our power at that point. That takes another decade or two to get to that point — if this pathway turns out to be the right pathway to go down.Ali, thanks for coming on the podcast.No problem. It's my pleasure. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit fasterplease.substack.com/subscribe

Martha L. Gray, Professor, Electrical Engineering & Computer Science and Institute for Medical Engineering & Science, MIT, entrevista por Mercedes Delgado, Associate Professor of Strategy and Innovation, Copenhagen Business School, and Research Scientist, MIT.

Dr. Elisseeff is the Professor Director of the Translational Tissue Engineering Center at Johns Hopkins Department of Biomedical Engineering.Jennifer received a bachelor's degree in chemistry from Carnegie Mellon University and a PhD in Medical Engineering from the Harvard–MIT Division of Health Sciences and Technology.  Jennifer's initial research efforts focused on the development of new biomaterials for medical implants, understanding stem cells and designing technologies. In recent years, she developed a passion for women's health and aging research– including the science behind adverse events to breast implants, new options to regrow tissue lost during lumpectomy, and deciphering the mechanisms behind fibroid development. On this podcast we discuss the very common issue of fibroids, what they are and their risks as well as aging and those treatments, yes Botox! 

We're a bit late this month! Life has been lifing and we're lifing with it. This month it's all about Music. Hanny talks about Music in magic. Liz covers Binaural beats. Resources for Music and Magickhttps://otherworldlyoracle.com/music-magick/https://qedavathegrey.tumblr.com/post/129182763268/music-in-witchcrafthttps://www.reddit.com/r/witchcraft/comments/u7fpql/music_and_magick/Vincent Price album - https://www.amazon.com/gp/product/B003URC5US/ref=as_li_tl?ie=UTF8&camp=1789&creative=390957&creativeASIN=B003URC5US&linkCode=as2&tag=dangeminds05-20&linkId=IUASEO45SCNIJA6MThe Paper Magician Trilogy by Charlie N. HolmbergThe song is 'In the Middle of the Night by Elley Duhé - https://vimeo.com/695429462Resources for Binaural Beats:Barratt, M., Maddox, A., Jenny L. Davis, J. & Smith, N., 2022. What are 'binaural beats' and do they affect our brain?. [Online] Available at: https://www.abc.net.au/news/2022-04-01/what-are-binaural-beats-do-they-affect-our-brain/100956002 [Accessed 7 May 2022].Cade, M., 2018. Binaural Beats for Relaxation, Meditation, Focus & Creativity. [Online]  Available at: https://www.mindlikewaterwellbeing.com/post/binaural-beats-for-relaxation-meditation-focus-creativity [Accessed 7 May 2022].Cafasso, J., 2021. Do Binaural Beats Have Health Benefits?. [Online] Available at: https://www.healthline.com/health/binaural-beats [Accessed 7 5 2022].Debbal, Y. N. E. H. B. & Sidi, M. E. A., 2021. Digital drugs (binaural beats): how can it affect the brain/their impact on the brain. Journal of Medical Engineering & Technology, 45(7), pp. 546-551.Drake, M., 2008. Binaural Beats for the Shamanic Journey. [Online]  Available at: https://shamanicdrumming.com/binaural_beats.html [Accessed 7 May 2022].Jirakittayakorn, N. & Wongsawa, t. Y., 2017. Brain Responses to a 6-Hz Binaural Beat: Effects on General Theta Rhythm and Frontal Midline Theta Activity. International Journal of Psychophysiology, 28(11), p. 365.Luna, A., 2022. How to Use Binaural Beats to LET GO of Fear, Pain, and Overthinking. [Online]  Available at: https://lonerwolf.com/binaural-beats-meditation/ [Accessed 18 May 2022].Wikipedia contributors, 2022. Beat (acoustics). [Online]  Available at: https://en.wikipedia.org/w/index.php?title=Beat_(acoustics)&oldid=1079816311   [Accessed 7 May 2022].Witch Bites Socials:Facebook - Witchy Bites Podcast Instagram: Witchy Bites (@witchy.bites)Opening/Closing songIndie Folk (King Around Here) | Royalty Free Music - Pixabay

Cait Thomas has a resume of experience and wisdom that will, quite simply, blow your mind. Cait has already accomplished so much during her career as a biomedical engineer working across a number of fields. Cait is the perfect example of how a career in engineering can lead you to fascinating corners of the medical industry that you never thought possible. From developing orthopaedic implants, to working on tech than can diagnose respiratory disease from the sound of a cough, to her current role at Vaxxas; a med-tech company developing a novel needle-free vaccine delivery system. Cait has lived an admirable career so far!  This episode is hosted by two of The University of Queensland's Women in Engineering student leaders; Laura Musgrave and Esandi Kalugalage. Connect with Cait on LinkedIn here: https://www.linkedin.com/in/cait-thomas/Connect with Laura on LinkedIn: https://www.linkedin.com/in/laura-musgrave-ab02821a6/Connect with Esandi on LinkedIn: https://www.linkedin.com/in/esandi-kalugalage-9b39401a0/ 

Rob Joseph is a co-founder of Anti Ordinary, a startup that have developed a beanie that is as safe as a helmet. Intrigued? So were we! Rob studied an undergrad of Medical Engineering, with the hope to combine his love for sport and engineering into a career. Originally eyeing off prosthetics for sport, his attention turned to brain protection after experiencing first-hand the pain points of brain protection in action sports. Rob teamed up with his co-founder Brodie to change the way we protect brains across all categories, starting in the unlikely market of Snowsports – and thus, Anti Ordinary was born. This episode is hosted by two of The University of Queensland's Women in Engineering student leaders; Jessica Rock and Kathleen Cox. For more information about Anti Ordinary, follow this link: https://antiordinary.co/ Connect with Rob on LinkedIn: https://www.linkedin.com/in/robjosephanti/Connect with Jessica on LinkedIn: https://www.linkedin.com/in/jessica-rock-447223165/Connect with Kathleen on LinkedIn: https://www.linkedin.com/in/kathleen-cox-142286184/

Treffen sich eine Biologin, ein Maschinenbauer und ein Orthopäde – was erstmal wie der Einstieg eines Witzes unter Forschenden klingt, ist tatsächlich ein sehr erfolgreiches Dreiergespann bei uns an der Universität! Denn Prof. Thorsten Halle von der Fakultät für Maschinenbau, die Biologin Prof. Jessica Bertrand und der Orthopäde Prof. Christoph Lohmann forschen gemeinsam an neuen Werkstoffen für Implantate. In der neuen Folge des Podcast „Wissen, wann du willst“ spricht Lisa Baaske mit Prof. Halle und Prof. Bertrand darüber, wie es zu der Zusammenarbeit kam, was die Vorteile, aber vielleicht auch Probleme sind und warum es wichtig ist, Implantate zu verbessern. Heute zu Gast Prof. Dr.-Ing. Thorsten Halle ist Leiter des Lehrstuhls Metallische Werkstoffe am Institut für Werkstoff- und Fügetechnik der Uni Magdeburg und Prof. Dr. Jessica Bertrand leitet das Forschungslabor der Orthopädischen Universitätsklinik. Gemeinsam mit Prof. Dr. Christoph Lohmann, Direktor der Orthopädischen Universitätsklinik, wollen sie in einer Arbeitsgruppe herausfinden, wie Endoprothesen im Körper wirken, insbesondere die Abriebpartikel, die täglich entstehen, wenn diese Implantate im menschlichen Organismus belastet werden. Eingebettet ist das ungewöhnliche Forschungsprojekt in das Promotionsprogramm MEMoRIAL, eine vom Europäischen Sozialfonds ESF geförderte Graduiertenschule. MEMoRIAL steht dabei für „Medical Engineering and Engineering Materials“. In diesem Programm werden internationale Promovierende in zwei besonders forschungsstarken ingenieurwissenschaftlichen Profillinien der Universität unterstützt: der Medizintechnik und den Materialwissenschaften. Ab dem Wintersemester wird es außerdem den neuen Master „Biomechanical Engineering“ geben, in dem sich Studierende für das Profil Endorprothetik entscheiden können.

We hope you enjoy our entrepreneur podcast! To help us grow, please subscribe to our podcast and follow us on YouTube, Instagram, Facebook and/or LinkedIn. It's the best way we can keep bringing in quality guests.Welcome to Business Over Drinks, one of the most unique podcasts you will find anywhere in the world helmed by two people from different walks of life.The podcast is an extension of their real-life experiences as business owners, salaried employees and industry mavericks who made mistakes along the way and lived to talk about it.WE SPEAK TO: Robert JosephRob is a Queensland born and bred startup founder. Spending most of his younger years playing any sport he could get his hands on, he found his own path in action sports. Initially dirt bikes, moving on to mountain bikes and then a stint competing at cable wakeboarding, he found his true sporting love of snowboarding late in life at age 17.When not chasing adrenaline, he'd spend most of his time tinkering. After school, he started an undergrad of Medical Engineering, with the hope to combine his loves of sport and engineering into some form of career. Originally eyeing off prosthetics for sport, his attention turned to brain protection after experiencing first-hand the pain points of brain protection in action sports. After a look around, he realised there wasn't really anything interesting or progressive happening in brain protection, so he teamed up with his co-founder Brodie to change the way we protect brains across all categories, starting in the unlikely market of Snow sports.Rob is the co-founder of Anti-Ordinary. A company that is aiming to revolutionise snow sports, starting with super protective head gear with the twist of it looking exactly like a beanie. But we'll find out more about that soon. WE'RE DRINKING:David: Fistful ShirazTerng: Suntory -196℃ 日向夏Rob: Stone & Wood Pacific AleWE CHAT ABOUT:The Anti-Ordinary Journey: How it began, where it's going and status updatesAnti-Ordinary vs the Big Name CompetitorsOn building the product and what it's likeWhat it's like working with a China teamTips on cash flowThe serendipitous meeting between Rob and their first investor: MattCrazy shenanigans and tests done during pitchesWhy founders should just brawl it outWhy kickstarters aren't what you think they areThe importance of finding the right partnersGuest Book Recommendations: Shoe Dog by Phil KnightThe SearchAny book on Keith Harring- Here's our pick (Keith Harring Journals)! 

Prof Ellen Roche, Associate Professor in the Department of Mechanical Engineering and the Institute of Medical Engineering and Science at MIT joins me this week. She directs the Therapeutic Technology Design and Development Lab at MIT and her research focuses on applying innovative technologies to the development of cardiac devices. She chats to me about growing up in Galway, her experiences in California working in medical device engineering and why she decided to leave industry to do a PhD in Harvard as a Fulbright Scholar.  She describes her work using soft robotic approaches to augment heart function and her collaborations with Boston's Children's Hospital.  She also discusses juggling family life & academia and how most of her work 'gets done when the kids are gone to bed'.  Follow Ellen: ellentroche Follow me: MeganHanlon4 This season is kindly sponsored by Bio-Sciences Ltd, now part of Thermo-Fisher Scientific.

(3:00) - Starfish-inspired Robot ⭐️

Jim Collins is The Termeer Professor of Bioengineering in the Department of Biological Engineering and Institute for Medical Engineering & Science @ MIT. He is also affiliated with the Broad Institute and the Wyss Institute. His research group works in synthetic biology and systems biology, with a particular focus on using network biology approaches to study antibiotic action, bacterial defense mechanisms, and the emergence of resistance. Professor Collins' patented technologies have been licensed by over 25 biotech, pharma and medical devices companies, and he has helped to launch a number of companies, including Senti Bio, Sample6 Technologies, Sherlock, Synlogic, and EnBiotix. He has received numerous awards and honors, including a Rhodes Scholarship, a MacArthur "Genius" Award, an NIH Director's Pioneer Award, a Sanofi-Institut Pasteur Award, as well as several teaching awards. Professor Collins is an elected member of the National Academy of Sciences, the National Academy of Engineering, the Institute of Medicine, and the American Academy of Arts & Sciences, and a charter fellow of the National Academy of Inventors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

Ute Marx is Professor of Medical Engineering at Pforzheim University, but she has spent some of her research time in Brisbane Australia. Her teaching focuses on the subjects of technical sales and marketing, as well as natural science subjects such as molecular biophysics and metabonomics. Her research activities focus, among other things, on the question of how metabolic products in body fluids can provide information about the course of diseases and the success of therapies. Her interest in algae research started in 2005 studying the metabolism of H2 producing algae. John Roles is a research fellow at the Institute for Molecular Bioscience at the University of Queensland, Australia. Together with Professor Ben Hankamer he researches the economic potential of algae generated products. He has over 35 years of experience in the design and construction of energy projects including power generation and renewable fuels. His PhD was directed at the generation of the TELCA platform for economic and environmental assessment of renewable fuel production. Professor Ben Hankamer is from the University of Queensland. He is the group leader of Bioinspired design of solar biotechnology systems lab group and the Director of the Centre for Solar Biotechnology, as well as the founding director of the Solar Biofuels Consortium. The Centre for Solar Biotechnology focuses on developing next generation microalgae systems tapping into the huge energy resource of the sun capturing CO2 to produce a wide range of products. Listen to the episode to hear about: Introduction (2:35) What sargassum is to Ute and John (5:05) How Ute and John began working with sargassum (8:29) Solar biotech (14:20) Making crude oil (16:46) Using sargassum vs land-based algae (18:37) Biotech locations (22:41) Base case scenario and number estimates of operation (26:07) Future plans and turning theory into reality (38:07) Additional comments from Ute and John (43:19) Debrief (45:45) Episode Transcript Learn more about Ute Marx and John Roles: ֍ Bioinspired Design of Solar Biotechnology Systems Lab Group ֍ Professor Ben Hankamer ֍ Sargassum blooms in the Atlantic Ocean- From a burden to an asset We love to hear from you, feel free to drop us an email to SargassumPodcast@gmx.net, and connect with us on social media: Facebook, twitter, Instagram, LinkedIn. Can't get enough? Become one of our patrons for as little as $1 a month. Patrons get to submit questions to us prior to the interviews that we will then ask our guests. We are grateful for each supporter and look forward to connecting with you. Like our music? This song is called Them Ah Prey by Drizzle Road Ranna. Follow him on YouTube and Spotify

During a session at Sanders Theatre, Harvard Medical School, on “Memory, Consciousness, and Coma” on May 14, Emery N. Brown, MD, PhD, Warren M. Zapol Professor of Anesthesia at Harvard Medical School and at Massachusetts General Hospital, Edward Hood Taplin Professor of Medical Engineering and Professor of Computational Neuroscience at MIT; and Nicholas D. Schiff, MD, PhD, The Jerold B. Katz Professor of Neurology and Neurosciences, Weill Cornell Medical College,New York, seek Sadhguru's inputs on various aspects of anesthesia, the brain and science. 00:00 Conversation Starts 01:52 - Professor's explanation on how anesthesia affects your brain. 06:50 - Sadhguru's explanation on difference between consciousness and jaagrithi (wakefulness). 22:45 - How can we use the yogic insights and adapt them into anesthesiology ? 30:17 - People lose sense of time both during enlightenment and during anesthesia. Why ? 37:49 - Discussion on space and time from a yogic perspective. 42:21 - How can we use your enlightenment experiences to solve the issues in the world ? 1:02:33 - How can we put aside memory and intelligence when those are the biggest gifts to us ? 1:19:17 - What are your thoughts on near-death experience ? Sharing Sadhguru's wisdom to all More wisdom, join us in your favorite social media.. Tiktok : https://www.tiktok.com/@sadhguruji Snapchat : @sadhgurustory Instagram : https://www.instagram.com/sadhgurustory/ Feel free to make any suggestions Download and share as you wish Let peace and joy be the fundamentals of your life

An interview with Jordan Harrod, a PhD Candidate in the Harvard-MIT Health Sciences and Technology program, a YouTuber who creates educational videos about AI, and an advocate for evidence-based policy. Subscribe: RSS | iTunes | Spotify | YouTube Check out her channel at https://www.youtube.com/c/JordanHarrod Detailed bio: Jordan Harrod is a Ph.D. Candidate in Medical Engineering and Medical Physics at the Harvard-MIT Health Sciences and Technology program. Her research focuses on using neuromodulation to understand pain and consciousness, and using neurotechnology and machine learning to develop new tools for brain stimulation. She is also a significant communicator and educator focused on AI, with her YouTube channel having many videos on how we interact with artificial intelligence in our daily lives, and she is also the Chief Operating Officer of the MIT Science Policy Review, a peer-reviewed science policy journal. Music: Deliberate Thought, Inspired by Kevin MacLeod (incompetech.com)

General Anesthesia and Altered States of Arousal: A Systems Neuroscience Analysis, Clinical Electroencephalography for Anesthesiologists, and Multimodal General Anesthesia: Theory and Practice. Prof. Emery Brown is Professor of Anesthesia at Harvard Medical School and Professor of Medical Engineering and computational neuroscience at Massachusetts Institute of Technology. His lab develops statistical methods and signal-processing algorithms for neuroscience data analysis. --- Send in a voice message: https://anchor.fm/scientificsense/message Support this podcast: https://anchor.fm/scientificsense/support

Quota For Govt School Students In Medical & Engineering Courses Stay tuned for all the breaking news ! Visit Our Website https://odishatv.in/ News In Odia: https://khabar.odishatv.in/ Android App: https://bit.ly/OTVAndroidApp iOS App: https://bit.ly/OTViOSApp Watch Live: https://live.odishatv.in/ YouTube: https://goo.gl/Ehz6OP Facebook: https://www.facebook.com/otvnews OTV English Facebook : https://www.facebook.com/otvenglish OdishaTV is Odisha's no 1 News Channel. OTV being the first private satellite TV channel in Odisha carries the onus of charting a course that behoves its pioneering efforts. Accordingly its charter objectives are FREE, FAIR and UNBIASED. OTV delivers reliable information across all platforms: TV, Internet and Mobile.

Dr. Marzyeh Ghassemi will soon be part of MIT's Department of Electrical Engineering and Computer Science and its Institute for Medical Engineering and Science faculty. And she is quick to call out the lack of representation in the data we collect to build products and services across industries. Including for women, who are not a minority -- but an often ignored majority. Currently an Assistant Professor at the University of Toronto in Computer Science and Medicine and a Vector Institute faculty member holding a Canadian CIFAR AI Chair and Canada Research Chair, Marzyeh has no shortage of accolades or degrees. She is an Oxford alum, as a Marshall Scholar. She also has 3 kids. About Marzyeh Marzyeh's plug, Muslims in Machine Learning Marzyeh's other plug, apply to MIT! About the host + the pod: Follow Layla on Instagram Follow Muslims Doing Things on Instagram Fun fact - this is the first episode ever recorded! Pardon my audio quality, I was figuring out the ropes. About me & the pod: Follow the host (@laylool) on Instagram Follow Muslims Doing Things on Instagram --- Send in a voice message: https://anchor.fm/laylool/message

During a session at Sanders Theatre, Harvard Medical School, on “Memory, Consciousness, and Coma” on May 14, Emery N. Brown, MD, PhD, Warren M. Zapol Professor of Anesthesia at Harvard Medical School and at Massachusetts General Hospital, Edward Hood Taplin Professor of Medical Engineering and Professor of Computational Neuroscience at MIT; and Nicholas D. Schiff, MD, PhD, The Jerold B. Katz Professor of Neurology and Neurosciences, Weill Cornell Medical College,New York, seek Sadhguru's inputs on various aspects of anesthesia, the brain and science.[divider]Editor's Note: Connect with Sadhguru! Download the Sadhguru App and get access to Sadhguru's articles, videos, daily quotes, program info and much more. Available on Android and iOS. Conscious Planet: https://www.consciousplanet.org Sadhguru App (Download): http://onelink.to/sadhguru__appOfficial Sadhguru Website: http://isha.sadhguru.orgSadhguru Exclusive: https://isha.sadhguru.org/in/en/sadhguru-exclusiveSee omnystudio.com/listener for privacy information.

Have you ever faced a problem that seems insurmountable, only to have someone come along, view it from a different perspective and find a solution? That is the business model for the IMAGE Center of Maryland. Executive director Michael Bullis explains how the non-profit connects people with disabilities to solutions to help regain independence in their lives. Plus, we talk with Rhonda Taylor and Shannon Clancy to learn about Volunteers for Medical Engineering -- one-off devices that are tailored to a client’s needs.

Emery Neal Brown | Anesthesiology and Consciousness Host David Bramante speaks with Emery Neal Brown about his recent award from the Society of Neuroscience (SfN) (the Swartz Prize) for Theoretical and Computational Neuroscience, and discusses his research and experience with anesthesia and consciousness, including the black box of neuroscience, burst suppression, computational neuroscience, and several research programs that he's involved in. Emery is the Warren M. Zapol Professor of Anesthesia at Harvard Medical School and at Massachusetts General Hospital (MGH), and a practicing anesthesiologist at MGH. At MIT he is the Edward Hood Taplin Professor of Medical Engineering and professor of computational neuroscience, the Associate Director of the Institute for Medical Engineering and Science, and the Director of the Harvard–MIT Program in Health Sciences and Technology. He is also one of only 19 individuals who has been elected to all three branches of the National Academies of Sciences, Engineering, and Medicine, as well as the first African American and the first anesthesiologist to be elected to all three National Academies. Learn more about Emery here: https://en.wikipedia.org/wiki/Emery_N._Brown Listen on Spotify: https://open.spotify.com/episode/1fmWufR6vdGbsrQg0F3ZGS?si=7O2xecO2QUSicUgGwVdR_w Listen on Apple Podcasts: https://podcasts.apple.com/us/podcast/the-david-bramante-show/id1525266196#episodeGuid=849441c3-0cdd-4135-b3f5-039d182cdec3 Watch on YouTube: https://youtu.be/GmYuwHzCO4w PS. Emery discusses that he prefers Star Trek over Star Wars at the end of the show, and that his favorite episode is called Ultimate Computer. Check it out: https://en.wikipedia.org/wiki/The_Ultimate_Computer About this show: The David Bramante Show | Discussing the relationship between humans, machines and the future. Host David Bramante researches and reads a massive amount of books on consciousness, neuroscience, artificial intelligence, tech singularity, robots, robotics, and futurism. He talks to cutting-edge researchers, scientists, and futurists, to learn more about where we're headed as a species. For more info, visit https://www.DavidBramante.com

Jordan Harrod is a PhD student in Medical Engineering and Medical Physics at the Harvard-MIT Health Sciences and Technology program. She works at intersection of non-invasive brain-machine interfaces and deep learning for clinical pain and anesthesia under Dr. Ed Boyden and Dr. Emery Brown. Her YouTube channel focuses on engaging the public on artificial intelligence and algorithms. She received her Bachelor of Science in Biomedical Engineering from Cornell University in 2018. You can follow her on Twitter @JordanBHarrod.

Jim Collins, bioengineer, and Termeer Professor of Medical Engineering & Science and Professor of Biological Engineering at MIT. on "Designing Science" podcast with Arvind Gupta, Founder and Managing director of IndieBio. IndieBio is a leading seed-stage life science accelerator program devoted to funding and building startups dedicated to solving humanity’s most pressing problems through biology. We enable the best scientists to become entrepreneurs, and nurture the future leaders of movements and systemic change. Our technology focus is on reinventing the food and water supply chain, medicine, healthcare, diagnostics, agriculture, and biomaterial industries. To date, 116 companies have graduated from the program, with a combined current valuation of over $2B. IndieBio is a member of SOSV a $700M global fund focused on lasting impact.

In the seventh episode of the "You Belong in AI!" podcast, ACM AI Outreach @ UCLA interviews Jordan Harrod (she/her/hers). Jordan is a PhD student in Medical Engineering and Medical Physics at the Harvard-MIT Division of Health Sciences and Technology program. She works at the intersection of non-invasive brain-machine interfaces and deep learning for clinical pain and anesthesia under Dr. Ed Boyden and Dr. Emery Brown. She received her Bachelor of Science in Biomedical Engineering from Cornell University in 2018. Her YouTube channel focuses on engaging the public on artificial intelligence. You can follow her on Twitter @JordanBHarrod. Listen to learn about Jordan's background and experiences in research, AI literacy and education, her Youtube channel, AI fairness and ethics, and her messages of encouragement to underrepresented students passionate about STEM! The "You Belong in AI!" podcast is made possible by ACM AI Outreach @ UCLA. All questions are contributed by Arjun Subramonian (Outreach Director 20-21), Maya Raman (Events Director 20-21), Kai Tota (Outreach/Events Officer 20-21), Jason Jewik (Outreach Officer 20-21), Mat Ruíz (Outreach/Events Officer 20-21), Aman Oberoi (Outreach Officer 20-21), and Nisha McNealis (Outreach Officer 20-21). The podcast is edited by Jason Jewik. The music you hear in this episode is: Cheery Monday by Kevin MacLeod Link: https://incompetech.filmmusic.io/song/3495-cheery-monday License: http://creativecommons.org/licenses/by/4.0/ Want to learn more about ACM AI Outreach @ UCLA? Visit our website and Twitter. Want to learn more about Jordan? Make your way to her website, YouTube channel, and Twitter.

When you’re a healthcare innovations startup poised to take that next step, nothing can throw you more of a curveball than a global pandemic. Right now, the market has slowed and is proceeding with caution, but ‘slow’ doesn’t mean ‘stop.’ Funding may be hard, but it’s not impossible - and there are actions every company can take that will help keep them relevant and active in the industry. In today’s episode, Surefhir Co-Founder and CEO, Ana Gomez del Campo gets candid with our listeners as she recounts how her company has weathered the impact of the go-stop-crawl process of the last few months. Ana shares her thoughts on being open to collaboration, willing to pivot, why it’s so important to know who you’re targeting when going to market.   Here are the show highlights: When crises slow an innovation’s forward trajectory, these actions can keep you relevant and active in your industry (4:03) A strong argument for collaboration and customer discovery (9:19) Why funding may be difficult, but certainly not impossible, during a pandemic (14:50) A quick dive into the psychology around why Angel Investors invest (17:41) How a partial pivot to innovation can yield surprising results (19:09) Why right now might be the time to open discussion about how your innovation may work for other potential target markets (22:03) How getting “lost in the fog” can sabotage your success (23:45) When listening to stakeholder advice produces that ah-ha moment (26:01) Recognizing the different value propositions between patient, provider, and those who write the checks are critical to innovation success (31:18) Guest Bio Ana Gomez del Campo is CEO and Co-Founder of Surefhir, a healthcare digital solution that aims to boost patient satisfaction and discharge efficiency with tools that keep patients, loved ones, and care teams all on the same page and up-to-date on a patient’s care journey. A recipient of several entrepreneurial and neuroscience grants and prizes, Ana graduated from the Georgia Institute of Technology with her BS in Biomedical and Medical Engineering. If you want to reach out to Ana, she can be reached via email at ana@surefhir.co, on LinkedIn at Ana Gomez del Campo, or for more information about the Surefhir solution, visit their website at surefhir.co

As the world grapples with the coronavirus pandemic, the topic of infectious diseases has taken centerstage in our public consciousness. While COVID-19 may be viral in nature, many of the most dangerous diseases are caused by bacteria. Medicine has traditionally treated these infections with antibiotics, but increasingly our antibiotics are becoming less and less effective. My guest today is Dr. Muhammad H. Zaman who joins me to discuss his new book Biography of Resistance: The Epic Battle Between People and Pathogens. Dr. Zaman is a professor of Biomedical Engineering and International Health at Boston University and his research has led him to become a Fellow with the American Institute of Biological and Medical Engineering. He has shared his expertise with newspapers across globe with columns appearing in over thirty countries. Dr. Zaman joins me via Zoom from his home in Massachusetts to discuss the evolutionary history of bacteria and the microscopic war that has occurred between them for millions of years, the first human efforts to understand these organisms and influence that battle, and how those efforts have led the world of medicine into an age of highly resistant "superbugs." For incredible gourmet freshly roasted coffee delivered to your door, check out Phil & Sebastian Coffee Roasters! Free shipping anywhere in the US or Canada! Want to listen to new episodes a week earlier and get exclusive bonus content? Consider becoming a supporter of the podcast on Patreon! Like the podcast? Please subscribe and leave a review! Follow @CMTUHistory on Facebook, Twitter, Instagram & TikTok --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

In this episode, we feature two experts in the field of translational medicine, Dr. Sanjiv Narayan and Dr. Elliott Chaikof. Dr. Narayan is a professor of medicine at Stanford University and cofounder of the Stanford Arrhythmia Center. Dr. Chaikof is the chair of the Department of Surgery at Beth Israel Deaconess Medical Center.Watch videos of Dr. Narayan and Chaikoff's grand rounds talks and these interviews on the DeBakey CV Education YouTube channel: Novel Mechanistic Insights in Atrial Fibrillation (Sanjiv Narayan, MD)Grand Rounds Interview with Sanjiv Narayan, MDBreaking Bad: Thrombosis and Bleeding in the Modern Era (Elliott Chaikof, MD, PhD)Grand Rounds Interview with Elliot Chaikof, MDWe'd love to hear your thoughts about translational innovation. Post your comments on Twitter with #CVnow and tag @debakeyCVedu, and be sure to follow @debakeyCVedu on all your social media platforms!

Dr. Joe Frassica (MED’88) has built an extraordinary career delivering healthcare innovations to the patient’s bedside. He is the Head of Philips Research and Chief Medical Officer at Philips North America. He also remains active in the world of academic medicine with teaching appointments through the Institute for Medical Engineering and Sciences at MIT and Massachusetts General Hospital. During this episode of the podcast, Joe reflects on the role of mentors who helped guide him in his remarkable journey and the lessons he learned about leading transformational change.This episode of Proud to BU is released in celebration of Alumni Career Weeks: New England. As a Cambridge-based Terrier, Joe has seen the power of this innovation economy and also shares a few reflections on the local partnerships he’s forged between Philips and Boston University.To keep up with all the great work Joe is doing at Philips and beyond, be sure to follow him on LinkedIn. For more on the Proud to BU podcast, visit bu.edu/proudtobu.Support the show (http://www.bu.edu/give)

During a session at Sanders Theatre, Harvard Medical School, on “Memory, Consciousness, and Coma” on May 14, Emery N. Brown, MD, PhD, Warren M. Zapol Professor of Anesthesia at Harvard Medical School and at Massachusetts General Hospital, Edward Hood Taplin Professor of Medical Engineering and Professor of Computational Neuroscience at MIT; and Nicholas D. Schiff, MD, PhD, The Jerold B. Katz Professor of Neurology and Neurosciences, Weill Cornell Medical College,New York, seek Sadhguru’s inputs on various aspects of anesthesia, the brain and science. [divider] Editor's Note: Connect with Sadhguru! Download the Sadhguru App and get access to Sadhguru’s articles, videos, daily quotes, program info and much more. Available on Android and iOS. 

Ira Pastor, ideaXme exponential health ambassador, interviews David Mittelstein, MD/PhD Student at California Institute of Technology and Keck School of Medicine of USC. Ira Pastor Comments: Today we are going to head back towards a major set of pathologies responsible in 2020 for what is a still a big portion of the $7 trillion global healthcare figure, and that’s cancer. Despite the major progress that has been made over the last century on improving patient outcomes and the period of so called “disease-free survival,” we still have an ugly set of numbers in front of us – World Health Organization (WHO) data is as follows for 2018: 18.1 million new cases of cancer and 9.6 million deaths. Today however, we are going to move away from some of the more traditional biological themes such as chemotherapy, immunotherapies, and "smart" check-point inhibitor drugs, and we are going to journey into the fascinating and unique bio-physical world of cancer, and specifically talk about an emerging discipline called Oncotripsy, which is defined as a method of selectively targeting cancer cells by means of ultrasound harmonic excitation of their resonance frequency (similar to how a trained singer can shatter a wine glass by singing a specific note). Now, as some may remember, we actually talked a little bit about this general domain a few months ago on the show where Professor Dr. Irena Cosic at RMIT Australia came on and discussed her Resonant Recognition Model (RRM) of macro-molecular interactions which proposes that protein (and other macro-molecule interactions) are based on highly specific resonant electromagnetic energies. David Mittelstein Today, we are joined by David Mittelstein, MD/PhD Student, at California Institute of Technology (CalTech), Keck School of Medicine of USC, and lead author on a recent paper, in Applied Physics Letters, entitled “Selective Ablation of Cancer Cells with Low Intensity Pulsed Ultrasound,” which gave a fascinating proof of concept for this new approach, which unlike other forms of therapy, doesn't require cancer to have unique molecular markers or to be located separately from healthy cells to be targeted. This work was done in collaboration between California Institute of Technology and City of Hope Beckman Research Institute. David attended the University of Southern California (USC) where he received his Bachelor of Science in Biomedical Engineering (Biochemical), and Caltech, where he received his Masters of Science in Medical Engineering. He is also the Founder and President of Vision for Vision, a non-profit student-run organization dedicated to raising awareness about eye care examinations for the early diagnosis of diseases like glaucoma. On this show we will hear from David: About his background, how he developed an interest in science, biomedical engineering, and how he finds himself in this fascinating domain of oncology research. An overview of Oncotripsy and the importance of studying the Bio-Physical world of cancer. His proof of concept Oncotripsy work and his future research visions. Finally, we’ll learn about the Vision for Vision project. Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter:@IraSamuelPastor If you liked this interview, be sure to check out our interview with Dr. Irena Cosic! Follow ideaXme on Twitter:@ideaxm On Instagram:@ideaxme Find ideaXme across the internet including oniTunes,SoundCloud,Radio Public,TuneIn Radio,I Heart Radio, Google Podcasts, Spotify and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.

I gotta admit, Caleb is one of the most well-spoken people I've met in my life. He's polite, he's eloquent, and he's a pleasure to talk to. This week Caleb takes me through BME and AMS, two majors that I have zero experience with, and he gives me an overview of how they work at Stony Brook University. He also talks about his passions in 3Diatrics, and his plans for attending medical school. I do sincerely hope that Caleb succeeds. He'd make a great doctor.

In the 1950s, Vladimir K. Zworykin, an engineer recently retired from research at RCA, looked at the rising cost of health care and the shortage of medical personnel in America, and decided to do something about it. His solution was to apply computer engineering techniques to the problems of health care and medical diagnosis. To do so, Zworykin established an interdisciplinary research group of engineers, statisticians, and physicians, and tasked them with developing computer programs capable of aiding medical diagnosis. In this episode of Stories from the Stacks, Andrew Lea, PhD candidate in the history of science and medicine at the University of Oxford, discusses the work of Zworykin and company, tracing the origins of the push for bio-medical computing, its uneven reception in the medical world, and the unfolding legacy the movement has left. The Zworykin project focused on hematology, and worked on diagnostic software to assist the identification of blood diseases. Translating a vast and incomplete body of organic conceptions of disease into objective, numerical, and standardized concepts legible to machines proved to be an almost insuperable challenge. Paper technologies, such as the Cornell Medical Index, that standardized medical data gathering, aided computerization. Using Hagley Library collections, including the Vladimir K. Zworykin papers, and the David Sarnoff Research Center records, Lea discovered that the advent of computer-aided diagnosis elicited mixed reactions from the medical profession. The first demonstration of the technology, which took place in 1957 at the RCA labs in Camden, NJ, sparked decades of debate over the art versus the science of medicine. Does computerization dehumanize health care, or does it rationalize and thereby improve health care? Is there a need for diagnostic programming when the majority of health care involves not diagnosis but ongoing disease management? Is human cognition reducible to computerized functions, or do computers undermine the clinical authority of the physician? Initially debated in the twentieth century, these questions continue to shape the twenty-first-century conversation about health care. To support his use of Hagley Library collections, Lea received a Henry Belin du Pont research grant from the Center for the History of Business, Technology, & Society. More information on funding opportunities for research at Hagley can be found at www.hagley.org/research/grants-fellowships. For more Stories from the Stacks, go to www.hagley.org, or subscribe on your favorite podcatcher. Interview by Amrys Williams. Produced by Gregory Hargreaves. Image: “Two of RCA Victor's famous staff of television research engineers, Dr. V.K. Zworykin (left) and E.W. Engstrom, examine a new piece of equipment at the Camden Laboratories.” Television, 1945-1950, PC20110303_456, Box 46, Chamber of Commerce of the United States photographs & audiovisual materials, Series II. Nation’s Biusiness photographs (Accession 1993.230.II), Audiovisual Collections & Digital Initiatives Department, Hagley Museum & Library, Wilmington, DE 19807.

In the beginning of my talk with newly minted MIT PhD Richard Fineman we talk about fellow Smart Athlete Podcast guest Greg Grosicki's advice for Richard throughout grad school and the secret he's been keeping from Richard. Since he's a newly minted PhD in Medical Engineering, Richard has been looking for employment both in the private sector and in Academia - he talks about the pros and cons of both and I share my opinion on one of the greatest moments in working in a private company developing unique products. We talk a little about whether altruism can actually be real. In the middle of my talk with Richard we discuss his research at MIT in Medical Engineering and human biomechanics as well as how some of this might be applied in the private sector. Richard shares his opinion on machine learning in society - how it can aid us and the potential downfalls of relying too heavily on AI decisions. He also gives me a little insight into what wearing a spacesuit feels like from his time working as a NASA fellow. In the last part of my chat with Richard I bring up the beer mile wager between him as well as former smart athlete podcast guests Greg Grosicki and Corey Robinson. Richard was the champion of that endeavor despite being the slowest runner so he shares with me his "secrets" to being the beer mile champ. We diverge as I ask him about becoming a certified yoga instructor - something that takes 200 hours of work to complete. He lets me know how yoga has affected his triathlon career and what has happened in the wake of not being as active with it anymore. Shop the Solpri store at https://solpri.com

Discover the history and enduring legacy of the iron lung, developed in the 1920s to aid individuals with polio. This episode delves into the medical advancements that improved the device and explores the experiences of those who lived and continue to live in this cylindrical breathing machine. Learn about the iron lung's lifesaving impact in the realm of medical history. #MedicalHistory #IronLung #Polio #MedicalEngineering #20thCenturyMedicine #PolioSurvivors Learn more about your ad choices. Visit podcastchoices.com/adchoices

*This episode was originally aired on Shrugged Collective on 7/22/19* "Since joining the team in 2008 as Assistant Director of Food & Beverage, his innovative, fresh ideas and determination have enabled him to quickly excel through the ranks, holding various positions at the resort including Director of Food & Beverage, Director of Rooms and Resort Manager. Flores’ multifaceted experience and familiarity with The Resort at Pedregal paired with his compassionate leadership skills allow him to further enhance the resort’s undisputed benchmark for providing the very finest in luxury hospitality and guest satisfaction. During his tenure, The Resort at Pedregal has been named the No. 1 Resort in Mexico by Travel + Leisure three times since the grand opening, was awarded the coveted Forbes Five-Star achievement for both the hotel and spa, and is consistently in the top 5 Resorts in Mexico (Western) in Condé Nast Traveler. Flores earned a Bachelor of Applied Science degree in Biomedical and Medical Engineering from the Universidad Autonoma de Guadalajara. "

In this first episode, I talk with John Gabrieli, Ph.D., who is often referred to as the smartest man alive and as soon as I heard him speak it's easy to understand why. John Gabrieli is the director of the Athinoula A. Martinos Imaging Center at the McGovern Institute for Brain Research at MIT. John uses imaging and behavioral tests to understand how the human brain powers learning, thinking, and feeling.  John Gabrieli;Principal Investigator, Harvard-MIT Division of Health Sciences and Technology (HST); McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, Massachusetts Insitute of Technology; Grover Hermann Professor, Health Sciences and Technology; Professor, Brain and Cognitive Sciences Director, Athinoula A. Martinos Imaging Center; Director, MIT Integrated Learning Initiative; Core Faculty, Institue for Medical Engineering and Science; Gabrieli Laboratory. (I told you he's the smartest guy on the planet) For more information on John Gabrieli's recent publications and cutting-edge research please visit http://gablab.mit.edu

As General Manager of The Resort at Pedregal, Fernando Flores brings more than 18 years of hospitality experience to the award-winning property. In his role, Flores is responsible for continuing the success of the prestigious resort while cultivating both domestic and international relationships with guests, colleagues and owners. From achieving financial results and implementation of capital expense projects and focusing on maintaining an efficient and profitable function of the day-to-day operations on property, to providing exceptional guest service and satisfaction property-wide, Flores has made an impact at the resort for over a decade.      Since joining the team in 2008 as Assistant Director of Food & Beverage, his innovative, fresh ideas and determination have enabled him to quickly excel through the ranks, holding various positions at the resort including Director of Food & Beverage, Director of Rooms and Resort Manager. Flores’ multifaceted experience and familiarity with The Resort at Pedregal paired with his compassionate leadership skills allow him to further enhance the resort’s undisputed benchmark for providing the very finest in luxury hospitality and guest satisfaction. During his tenure, The Resort at Pedregal has been named the No. 1 Resort in Mexico by Travel + Leisure three times since the grand opening, was awarded the coveted Forbes Five-Star achievement for both the hotel and spa, and is consistently in the top 5 Resorts in Mexico (Western) in Condé Nast Traveler.     Flores earned a Bachelor of Applied Science degree in Biomedical and Medical Engineering from the Universidad Autonoma de Guadalajara.    To say the Resort at Pedregal is phenomenal would be an understatement. The five-star resort is ranked by Forbes, TripAdvisor, and received Travel Leisure’s World’s Best Awards making it’s resume speak for itself. In today’s episode, Jason and Fernando discuss how reaching this degree of service and notoriety was possible. Through creating and maintaining a service culture rooted in harvesting meaningful connections and positive impact, The Resort at Pedregal is second to none when it comes to the service industry. With over a decade of experience, Fernando provides insight and takeaways for any business owner in today’s show. Enjoy!    Minute Breakdown:    0-5 – Getting Started in Customer Service Industry  5-10 – Creating and Maintaining Quality  10-15 – Rebranding: Communicating Mission and Vision  15-20 – Identifying Talent and Onboarding Process  20-25 – Making Your Team Gameday Ready   25-30 –Refining and Practicing Standards: Creating Alignment    Check out The Resort at Pedregal here: www.theresortatpedregal.com  Find The Resort at Pedregal at @resortatpedregal  Find Jason at @jasonkhalipa  Keep up with Jason’s latest project at: www.ncfitcollective.fit 

The field of engineering has many different branches and the University of South Florida does its best to have degree programs for all engineering disciplines. At ROBOTICON Tampa Bay, the team was joined by Abby, a sophomore biomedical engineering student. The biomedical engineering department was created only a year ago at USF and Abby is excited to be a part of the first class to go through the whole program. Even though the department is new, Abby talked about how she enjoys the coursework, and she looks forward to the more specialized classes such as the biomechanics labs.Also, Abby is glad that the university is working hard to help the student succeed in the program. She found out about the program during her freshman year and has been involved in it since. The department lets students go down various paths towards their career in the biomedical field. USF lets students choose whether they want to go towards graduate school, medical school, or straight into the technology industry. Abby started the program with no engineering background and she now she is enjoying it. Her plans are to get into biomechanics industry and gain more experience in the research field. Abby's dream is to work for NASA doing biomechanical research on how space affects the body and how to apply biomechanics to keep astronauts healthy in space. She is currently working in the research lab "CARRT" which specializes in rehabilitation research. She talks about how the bio-medical department can be feed into any engineering branch such as electrical, computer, mechanical or software engineering. To learn more about the Department of Medical Engineering go to their website.Sponsored by: Support our coverage by shopping Amazon here. Whether you're programming a robot, playing a game or doing homework, the Microsoft Surface is the tablet that can replace your laptop. Get yours at the Microsoft Store.

The field of engineering has many different branches and the University of South Florida does its best to have degree programs for all engineering disciplines. At ROBOTICON Tampa Bay, the team was joined by Abby, a sophomore biomedical engineering student. The biomedical engineering department was created only a year ago at USF and Abby is excited to be a part of the first class to go through the whole program. Even though the department is new, Abby talked about how she enjoys the coursework, and she looks forward to the more specialized classes such as the biomechanics labs.Also, Abby is glad that the university is working hard to help the student succeed in the program. She found out about the program during her freshman year and has been involved in it since. The department lets students go down various paths towards their career in the biomedical field. USF lets students choose whether they want to go towards graduate school, medical school, or straight into the technology industry. Abby started the program with no engineering background and she now she is enjoying it. Her plans are to get into biomechanics industry and gain more experience in the research field. Abby's dream is to work for NASA doing biomechanical research on how space affects the body and how to apply biomechanics to keep astronauts healthy in space. She is currently working in the research lab "CARRT" which specializes in rehabilitation research. She talks about how the bio-medical department can be feed into any engineering branch such as electrical, computer, mechanical or software engineering. To learn more about the Department of Medical Engineering go to their website.Sponsored by: Support our coverage by shopping Amazon here. Whether you're programming a robot, playing a game or doing homework, the Microsoft Surface is the tablet that can replace your laptop. Get yours at the Microsoft Store.

Dr. Emery N. Brown is a statistician, anesthesiologist and neuroscientist. He is the "Warren M. Zapol" Professor of Anesthesia at Harvard Medical School, as well as a practicing anesthesiologist. At MIT he is the "Edward Hood Taplin" Professor of Medical Engineering and Professor of Computational Neuroscience, as well as the Director of the Institute for Medical Engineering and Science, and the Director of the Harvard-MIT Health Sciences and Technology Program. Brown is also the first African American and first anesthesiologist to be elected to all three National Academies. Needless to say that Dr. Emery is one of the smartest individuals we've ever had on our Podcast, and a true hero of our time who works every day to make this world a better place for all of us. It was an honor talking to him about anesthesiology and neuroscience, I recommend you to sit back, take notes and listen carefully. Enjoy!

The Bicycle Network, Australia's largest cycling advocacy body, is calling for laws to be relaxed to allow cyclists to ride without helmets on paths where there isn't traffic. For the College's position on this issue, we hear from Professor Jeffrey Rosenfeld AC OBE, Director of the Monash Institute of Medical Engineering, Professor of Surgery at Monash University and a senior neurosurgeon at The Alfred Hospital in Melbourne. He shares his thoughts on the consequences of relaxing the current laws.

Professor Jeffrey Rosenfeld AC OBE is a globally acclaimed neurosurgeon, whose current project as Director of the Monash Institute of Medical Engineering is developing a bionic vision device to help people see again. It's a world away for the longstanding RACS Fellow who is a Professor of Surgery at Monash University and a senior neurosurgeon at The Alfred Hospital in Melbourne. He has spent considerable time on deployments in conflict zones overseas, where he has witnessed horrific injuries resulting from bomb blasts. He says the immediate action to stop bleeding by the use of tourniquets is a lesson first responders can apply in emergency situations back on home soil.

About this episode... Today we talk with Tuppy Owens and her work as a sex-positive activist and helping disabled individuals find their sexuality. But trust me, Tuppy has been a strong force in the UK and world sex and disability scene since the 70s. She has even been seen on stage performing burlesque to celebrate her birthdays... but you should listen to find out more about that... A little about Tuppy... Tuppy Owens was born in Cambridge. She gained a degree in zoology from Exeter University, and then worked in ecology in Africa and Trinidad. She settled in London and worked as a scientific administrator at the Natural Environment Research Council. Then, in the late 1960s, she established a sex education book publishing company, for which she wrote and published The Sex Maniac's Diary successfully between 1972 and 1995, and which she operated as a thriving business from her Mayfair flat — for example, the 1975 Sex Maniac's Diary was launched in August 1974 with a reception at the Bristol Hotel in London which was reported on the following day in the Financial Times. Tuppy Owens remains active in running Outsiders. At the same time, she also advises the promoter of the Sexual Freedom Ball to fund Outsiders, and the organizers of the fundraiser, The Erotic Awards, now called The Sexual Services and Entertainment Awards. Owens is now the chair of the Sexual Freedom Coalition. Back in the 90s Owens worked campaigning with Prostitution Pride, parades through London, which was funded by Arcadia events in North London. Owens has been working with the Bath Institute of Medical Engineering in the hope that they will be able to create sex toys that can be used by disabled people who, without them, cannot masturbate. Owens will be the editor of a forthcoming website, The School of Sex for Disabled People, which is being created by sexually experienced disabled people and those who provide them with sexual services. She is currently writing her autobiography. Great Documentary on the Outsiders and Tuppy on YouTube https://www.youtube.com/watch?v=ofzxzBRpKFM Links to more information on Tuppy: https://en.wikipedia.org/wiki/Tuppy_Owens

In partnership with IEEE EMBS. Over 60,000 people in the United States undergo anesthesia every day which makes Dr. Emery Brown's research on the effects of anesthesia on the brain pertinent and relevant in today's world. Not only is Dr. Brown a Professor of Computational Neuroscience and Medical Engineering at MIT, Professor of Anesthesiology at Massachusetts General Hospital and at Harvard Medical School, and a practicing anesthesiologist at Massachusetts General Hospital, he is also an IEEE Fellow and member of the IEEE EMBS Scientific Advisory Board. In short, Dr. Brown is extremely qualified to research anesthesia and the brain. In this IEEE Brain podcast episode, Dr. Brown shares how he started working in this field, his goals in researching anesthesia, how IEEE is contributing to understanding the brain and much more.

UC Riverside に交換留学されている萩原紀子さんをお迎えして、「一日一恥」の実践による自分の殻の破り方や、交換留学の応募手続きのお話しなどを伺いました。 Show Notes ［OU-HL］いちょう祭2017 (2017.4.30-5.1) - YouTube Deep阪大 vol.1 阪大謎の地下空間に迫る (2017) - YouTube ジャパン・バイオデザイン Machikane FM - 8: Medical Engineering & Innovation Osaka University English Speech Contest 2017 | CAREN 世界最軽量「⼿のひらサイズ 580ｇ」医療⽤ガンマ線可視化カメラを開発 — リソウ 「Osaka University Global Alumni Fellow」の称号を授与しました — 大阪大学 世界初！水から水素を高効率で生成できる光触媒を開発 — リソウ 大阪大学 法学部 法学科 UC Riverside Prince Edward Island - Wikipedia Anne of Green Gables - Wikipedia Venice Beach California Machikane FM - 14: Get Out of Your Comfort Zone 2017年6月16日(金) ラボカフェスペシャルfeaturingサーチプロジェクト 「『遊び』から見る人間の本質」 — 大阪大学 2017年6月17日(土)から18日(日) マイナビ国際派就職EXPO 2017 東京サマー 2017年6月20日(火) 第75回OSIPP政策フォーラム キャリア・セミナー 国連職員になる方法説明会 2017年7月4日(火) 大阪大学 産学共創本部キックオフシンポジウム — 大阪大学 2017年4月19日(水)から7月12日(水) 交換留学経験学生による留学相談 — 大阪大学 2017年4月26日(水)から8月5日(土) 第21回企画展 HANDAIロボットの世界 －形・動きからコミュニケーション そしてココロの創生へ－ — 大阪大学 2017年6月24日(土)から25日(日) San Francisco Pride 2017 2017年7月8日(土)から9日(日) San Jose Buddhist Church Obon Festival 2017

UCLA に交換留学されている森本有太さんをお迎えして、留学先での宇宙工学の授業やトライアスロン部の活動、また留学費用のお話しなどを伺いました。 Show Notes 山中伸弥先生講演会 in Berkeley JSPS San Francisco Office UCSF-Gladstone Center for AIDS Research (CFAR) 大阪大学日本酒サークルのコラボ日本酒「hajime」を使用した日本酒ケーキ「hajime cake」が阪大生協購買部にて好評発売中です！ Machikane FM - 12: Let's Get Started! 阪大薫る珈琲 OU-COFFEE あなたが食べたい食堂メニュー大募集！アイデアメニュー祭り２０１７ 心不全患者、ＩＴで自宅リハビリ　阪大が臨床研究へ：朝日新聞デジタル 平成29年度科学技術分野の文部科学大臣表彰に5名が受賞しました！ — 大阪大学 Machikane FM - 8: Medical Engineering & Innovation ジャパン・バイオデザイン 大阪大学 基礎工学部 システム科学科 機械科学コース Machikane FM - 14: Get Out of Your Comfort Zone 『宇宙兄弟』公式サイト International Space Station (ISS) UCLA NASA Jet Propulsion Laboratory (JPL) Boeing Cassini: Mission to Saturn USA Triathlon Collegiate Club National Championships 2017 UCLABruins.com | UCLA Athletics Santa Monica CA | Visitor Information, Hotels, Dining City Of Beverly Hills Johnson Space Center 2017年5月26日(金) 大阪大学グローバル産学連携イニシアティブ「中小企業海外展共創」JICAによる中小企業海外展開支援事業説明会 — 大阪大学 2017年4月19日(水)から7月12日(水) 交換留学経験学生による留学相談 — 大阪大学 2017年4月26日(水)から8月5日(土) 第21回企画展 HANDAIロボットの世界 －形・動きからコミュニケーション そしてココロの創生へ－ — 大阪大学 2017年5月21日(日) マラソン大会 Bay to Breakers 大阪大学 CENTER FOR GLOBAL INITIATIVES 1906 San Francisco earthquake - Wikipedia

北米同窓会10周年記念講演会より、八木雅和先生と谷口達典さんの講演「医工情報とイノベーション」の様子をお届けします。 Show Notes 気付いたら9月も残るところ一週間。 iTunesのReviewの書き方ご存知ですか？ 平成28年度秋季の卒業式・学位記授与式を挙行 「環境報告書2016」を公表しました 北米同窓会の様子がキャンベル地元紙「Campbell Express」にて掲載 大阪大学国際医工情報センター 大阪大学 大学院医学系研究科 循環器内科学 ジャパン・バイオデザイン 独立行政法人 地域医療機能推進機構 大阪病院 独立行政法人 国立病院機構 大阪医療センター 大阪大学医学部附属病院 2016年10月3日(月)から2017年2月14日(火) 教員による留学相談（平成28年度後期） 2016年11月5日(土) 阪大北米同窓会ロサンゼルス地区年次総会

Inside Ragon is the official podcast of the Ragon Institute of MGH, MIT, and Harvard. Join Liam Fitzgerald as he talks with some of the brightest minds in HIV/AIDS research. In this episode of Inside Ragon Liam sits down with Alex Shalek, PhD, to talk about the latest technologies driving immunological research including his work on nanoscale manipulation and measurement technologies such as single-cell RNA-sequencing. Dr. Alex Shalek is a Professor of Health Sciences and Technology at MIT, a Core Member at the Institute for Medical Engineering at MIT, and an Associate Member here at the Ragon Institute.

Dr Joe Smith is the Chief Medical & Science Officer at the West Health Institute and President of The West Health Policy Center. Originally trained in Medical Engineering and Physics he then pursued his MD training at Harvard. After 20 years as a practicing Electrophysiologist he became Chief Medical Officer for Guidant and Boston Scientific's Cardiac Rhythm Management Division. Named as one of the "Twenty People Who Make Healthcare Better' he also serves as faculty advisor to the University of Southern California, Johns Hopkins, Harvard & MIT and The Wellcome Trust. In this discussion we delve deep into the motivations to pursue a career in medicine, how the arc of your career can take many paths and the skills that physicians are valued most for in roles outside of traditional clinical care.  If you enjoyed this episode please ‘Subscribe‘ on iTunes or Stitcher.   Enjoy!   Selected Show Notes:   West Health Institute, La Jolla, California. West Health Policy Institute, Washington DC.  Meditations by Marcus Aurelius.  The Youngest Science: Notes of a Medicine-Watcher by Lewis Thomas. Twitter:  @JoeSmithMD

Professor Garth Johnson will describe how biomechanical engineering is improving joint replacement treatment for older people, in this annual lecture organised by the Bath Institute of Medical Engineering.